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Abstract
In this dissertation, we consider the problem of partitioning a set of k population with respect
to a control population. For this problem some multistage methodologies are proposed and their
properties are derived. Using the Monte Carlo simulation techniques, the small and moderate
sample size performance of the proposed procedure are studied.
We have also considered at statistical surveillance of various cancers in Louisiana.
Keywords: ANOVA, Benzene Exposure, Benzene Cluster, Cancer incidence, Cancer cluster, Cor-
rect partition, Probability of correct decision, Monte carlo simulations, Sequential Procedure,
Single-stage procedure, two-parameter negative exponential populations.
x
List of Tables
2.1 Equi-coordinate percentage points of b of a multivariate exponential distribution . . 35
2.2 Simulation Result when itersize = 2000,5000 and 10000 and n∗ = 25 . . . . . . . 38
2.3 Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 50 . . . . . . . 39
2.4 Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 100 . . . . . . 40
2.5 Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 200 . . . . . . 41
2.6 Simulation Result when itersize =5000 and n∗ = 400 . . . . . . . . . . . . . . . . 41
2.7 Simulation Result when itersize =5000 and n∗ = 800 . . . . . . . . . . . . . . . . 42
2.8 Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 25 . . . . . . . 43
2.9 Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 50 . . . . . . . 44
2.10 Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 100 . . . . . . 45
2.11 Simulation Result when itersize =10000 and n∗ = 400 . . . . . . . . . . . . . . . 46
2.12 Simulation Result when itersize =10000 and n∗ = 800 . . . . . . . . . . . . . . . 46
3.1 Simulation Result when itersize = 2000 and σ = 1 . . . . . . . . . . . . . . . . . . 53
3.2 Simulation Result when itersize = 5000 and σ = 1 . . . . . . . . . . . . . . . . . . 53
3.3 Simulation Result when itersize = 10000 and σ = 1 . . . . . . . . . . . . . . . . . 54
3.4 Simulation Result when itersize = 2000 and σ = 2 . . . . . . . . . . . . . . . . . . 54
3.5 Simulation Result when itersize = 5000 and σ = 2 . . . . . . . . . . . . . . . . . . 55
4.1 Association Between Benzene Exposure and Development of Cancers . . . . . . . 80
xi
Chapter 1
Introduction and Preliminaries
1.1 Introduction to Exponential Distribution
How long can a machine or an component of a machine can function as designed before it breaks
down? How long do we have to hold before the call service center takes our phone call? How long
do we have to wait until we see the next customer enter our restaurant? All these are questions
which one comes across in our daily life and they all are related to finding the time until a specific
event will occur.
Questions concerning the time it takes before a given event can occur are generally explained in
probabilistic terms using the exponential distribution or using some generalizations of it. Because
the waiting time is unknown, so it is appropriate to think of it as a random variable that distributed
exponentially. In general, the time x it take us to wait before a certain event occurs follows an
exponential distribution if the probability that the event occurs during a certain time period is
proportional to the length of that time interval. More specifically, the waiting time x follows an
exponential distribution if the conditional probability
P (t < X ≤ t+ s|X > t)
is approximately proportional to the length s of the time interval comprised between the times t and
t + s. This realistic property has been widely applicable in many practical situations, and, this is
the reason why the exponential distribution is commonly used to model waiting time distribution.
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The exponential distribution is characterized as follows:
f(x;λ) =
 λe
−λx if x ≥ 0 ;
0 if x < 0 .
(1.1)
The parameter λ > 0 is the parameter of the distribution, and is called rate parameter. If a random
variableX has this distribution, we often writeX ∼ Exp(λ). The cumulative distribution function
of this distribution is given by:
F (x;λ) =
 1− e
−λx if x ≥ 0 ;
0 if x < 0 .
(1.2)
A commonly used alternative way to express the probability density function (pdf) of an Exponen-
tial distribution is
f(x; β) =

1
β
e−
x
β if x ≥ 0 ;
0 if x < 0 .
(1.3)
where β > 0 is a scale parameter of the distribution and is the reciprocal of the rate parameter, λ.
The mean (expected value) of an exponential distributed random variable X with rate parameter,
as defined in (1.1) is
E[X] =
1
λ
. (1.4)
Meaning that if you receive phone calls at an average rate of 2 per hour, then you are expect to
wait half an hour for every call.
The variance of X as defined in (1.1) is given by
V ar[X] =
1
λ2
. (1.5)
And the reliability function for the density in (1.1) is given by
2
Rel(t) ≡ R(t) = e−λt = e− tm . (1.6)
The exponential distribution is a commonly used distribution in reliability engineering. Math-
ematically, it is a fairly simple distribution, which is used to model the behavior of units that have
a constant failure rate or units that do not degrade with time or wear out. In general, if the lifetime
of a machine is modeled by an exponential distribution of the form in (1.1), then λ is the failure
rate of the machine. Rel(t) = e−λt is the reliability of the machine at time t.
Since the exponential distribution enjoys the Markov property,
P (T > t+ s|T > t) = P (T > s), (1.7)
it can be easily verified that
Rel(t+ s|T > t) = Rel(s). (1.8)
For example, consider a fictitious situation under which we express the reliability of a terminal
which has been in operation for 3 years, we have
Rel(5|T > 2) = Rel(3), (1.9)
meaning that the probability that the terminal will last 3 years more after lasting 2 years, is the
same as the probability lasting 3 years from the start.
One commonly used generalization of the exponential distribution is the 2-parameter exponen-
tial exponential which is given by:
f(t) = σ−1e−(t−θ)/σ,
where θ is referred to as the location parameter and σ as the scale parameter.
3
The mean or the mean time to failure (MTTF) is given by:
T =
∫ ∞
θ
t · f(t)dt
=
∫ ∞
θ
t · σ−1 · e−t/σdt
= θ + σ = m.
Note that when θ = 0, the MTTF is the inverse of the exponential distribution’s constant failure
rate.
The standard deviation, σT , for the 2-parameter exponential is given by:
σT = σ.
One can also verify that the 2-parameter exponential cumulative density function (cdf), is given
by:
F (t) = Q(t) = 1− e−(t−θ)/σ,
and, the reliability function is given by:
R(t) = 1−Q(t) = 1−
∫ t−θ
0
f(x)dx = e−(t−θ)/σ.
In clinical trials the exponential distribution has been used routinely used when comparing
an interventions therapy to a control therapy for the cases where Markov property (1.7) is sat-
isfied. Some of the important papers that have applied the exponential distribution to determine
sample size includes: Pasternack and Gilbert (1971), Pasternack (1972), Rubinstein, Gail, and
Santner(1981), Taulbee and Symons (1983). In Gross (1987), the author has explained the reasons
why an exponential distribution has been useful in determining sample size. In Rubinstein, Gail
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and Santner (1981) the authors have developed sample size estimates when the log-rank test is
used to compare two treatment groups. Via Monte Carlo computer simulations, it is shown that
the long-rank test has roughly the same power as either the exponential or the Weibull assumption
model. Morgan (1985) also exploits this method in determining appropriate combinations of ac-
crual and follow-up periods in a clinical trial based on cost minimization. Also, the multivariate
exponential distribution been routinely used in the survival analysis area because quite often in
survival studies the response times are correlated. The (paired) time to relief are usually corre-
lated. The papers that considered bivariate exponential survival distributions are: Gumbel(1960),
Freund(1961), Marshall and Olkin(1967), Gross, Clark, and Liu(1971), Block and Basu(1974),
Gross and Lam (1981), Knapp, Cantor, and Gross(1986).
1.2 Parameter Estimation for Exponential Distribution
In the statistical literature there are several methods to derive the parameter estimates when the
distribution is assumed to be known. In this section, we have summarized two such methods
which are most commonly used.
1.2.1 Maximum Likelihood Estimation
In general, the Maximum likelihood estimation technique uses the available data to construct a
likelihood function which is then used to find the values of the parameter estimates that maximize
the likelihood function. Suppose, a given variable X is exponentially distributed and the rate
parameter λ is to be estimated. Then, the likelihood function, given an independent and identically
distributed sample x = (x1, . . . , xn), is given by:
L(λ) = Πni=1λexp(−λxi)
= λnexp(−λΣni=1xi)
5
= λnexp(−λnx)
where:
x =
1
n
n∑
i=1
xi (1.10)
is the sample mean.
The derivation of the likelihood function’s logarithm is:
d
dλ
ln(L(λ)) =
d
dλ
(nln(λ)− λnx)
=
n
λ
− nx

> 0 if 0 < λ < 1
x
;
= 0 if λ = 1
x
;
< 0 if λ > 1
x
.
Consequently the maximum likelihood estimate for the rate parameter is:
λ̂ =
1
x
.
1.2.2 Bayesian Estimation
In Bayesian probability theory, if the posterior distribution p(θ|x) and the prior probability distribu-
tion p(θ) are in the same family, then the posterior and prior are called conjugate distribution, and
the prior is called a conjugate prior for the likelihood function. For instance, the Gaussian family
is self-conjugate to Gaussian likelihood function if the likelihood function is Gaussian. In order
to have the posterior distribution to be Gaussian, one needs to choose a Gaussian prior over the
mean. This means that Gaussian distribution is a conjugate prior for its likelihood function which
is also Gaussian. Similarly, the conjugate prior for the exponential distribution is the gamma dis-
tribution (of which the exponential distribution is a special case). The following parametrization
of the gamma probability density function is useful:
6
Gamma(λ;α, β) =
βα
Γ(α)
λα−1exp(−λβ). (1.11)
The Posterior distribution p can be expressed as:
p(λ) = Gamma(λ;α + n, β + nx). (1.12)
Note that the parameter α can be interpreted as the number of prior observations, and, β as the
sum of the prior observations. Giving the posterior mean as:
α + n
β + nx
. (1.13)
1.3 Literature Review for the Selection and Ranking Procedures
In our daily life, among the available choices, one often selects the best drug, best product, best
machine, etc. Customarily, analysis of variance (ANOVA) technique has been used to compare
several treatments with one another via a F-test using some prespecified level of significance α.
Under this F-test, the null hypothesis states that all the possible treatment effects under consider-
ation are equal, and, the alternative hypothesis states that at least one treatment mean is different.
In reality, we almost always reject null hypothesis at a reasonable level of type I error α. After all,
how realistic is the assumption that we have a number of different treatments but in reality they are
all same! The ANOVA approach then relies on the multiple comparison procedures such as LSD
method, or Tukey’s method, to name a few, in order to determine which means are different from
the rest. Quite often experimenter’s have used such ANOVA and multiple comparison procedures
to select the population with the largest mean as the best treatment without paying attention to the
probability requirement. It is important to note that if the ANOVA test was conducted with sig-
nificance level α then 1− α is not the probability that the treatment with the largest sample mean
has also the largest population mean. In many practical situations, the experimenter may wish to
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acquire more in-depth information and identify the treatment that is primarily contributed to the
rejection of the null hypothesis in ANOVA test. On the other hand, the experimenter may also be
interested in ordering all possible choices of treatments from the “worst” to the “best”. The area
of multiple comparisons is designed to study such and other related issues, and the Selection and
Ranking procedures were developed to solve this goals.
In the fifties, researchers such as Bahadur (1950), Bechhofer (1954) and Gupta (1956) devi-
ated from the traditional ANOVA approach and introduced in remarkable new methodologies in
section and ranking area. Bechhofer 1954, first introduced indifference zone concept to formulate
the methodologies for the problem of selecting the best from a set of several treatments.A solu-
tion offered by indifference-zone selection is to guarantee to select the best population with high
probability whenever it is at least a user-specified amount δ∗ better than the others. This approach
is known in the literature as the indifference-zone approach. Then, Gupta 1956 gave an alternative
approach to select the best treatment. This approach is a screening device that selects a random
size subset of competing alternatives that contains the best treatment, with prespecified probability
p∗, without specifying an indifference amount. This approach is known in the literature as the
subset selection approach.
Let pi0, pi1, . . . , pik, be (k + 1) independent and normal distributed populations with means
µ0, µ1, · · · , µk and a common variance σ2; and let pi0 denote the standard or control population.
Given arbitrary but fixed constant δ1 and δ2, and δ1 < δ2, define three subsets along the lines of
Bechhofer’s (1954) indifference zone formulation, as
ΩB = {pii : µi ≤ µ0 + δ1, i = 1, · · · , k},
ΩI = {pii : µ0 + δ1 < µi < µ0 + δ2, i = 1, · · · , k},
ΩG = {pii : µi ≥ µ0 + δ2, i = 1, · · · , k}.
(1.14)
We refer to ΩG as the set of “good populations” and ΩB as the set of “bad populations”. The
set ΩI would be referred to as the set of “indifference populations”. Adopting the Bechhofer’s
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indifference zone approach, we are interested in the correct partition of the populations in ΩG and
ΩB. And, we will be indifferent to partition of populations in ΩI . That is, with high accuracy we
want to partition the set Ω into two disjoint subsets PB and PG, such that, ΩB ⊆ PB and ΩG ⊆ PG.
Such a partition is known in the literature as a correct decision (CD). In other words, given a
pre assigned number P ∗, 2−k < P ∗ < 1, we seek statistical methodologies ℘ to determine PL and
PR, such that
P{CD|µ, σ2, ℘} ≥ P ∗ ∀ µ ∈ Rk+1, σ ∈ R+. (1.15)
Dunnett 1955 has considered a problem of comparing several treatment means with the control
mean with a common unknown variance for normal distribution. Letting X0, X1, · · · , Xp be the
means of p+ 1 treatments which are assumed to be pooled and normally distributed, X0 referring
to the control and using s be an independent estimate of the common standard deviation of the
p+ 1 sets of observations. Dunnett (1955) present a procedure to get the confidence limits for the
p comparisons X i − X0. The procedure had the property that the probability of all p statements
being simultaneously correct is equal to a specified value, P . Suppose there are N0 observation
on the control, N1 observations on the first treatment, · · · , Np observations on the p-th treatment.
Then these observations can be denoted by X ij(i = 0, 1, · · · , p; j = 1, 2, · · · , Ni), and the i-th
treatment means by X i.
Then, for the case p = 1, where there is only one treatment to be compared with the control.If
we write
z =
X1 −X0 − (m1 −m0)√
1
N1
+ 1
N0
, (1.16)
a lower limit on m1 −m0 will be given by
(X1 −X0)− d′s
√
1
N1
+
1
N0
,
9
if d′ is chosen so that
Prob(t < d′) = P.
Similarly, an upper confidence limit is given by
(X1 −X0) + d′s
√
1
N1
+
1
N0
,
The two-sides confidence limits for m1 −m0 will be given by
(X1 −X0)± d′′s
√
1
N1
+
1
N0
where d′′ is chosen to satisfy
Prob(|t| < d′′) = P.
The constant d′ or d′′ can be obtained from tables of the percentage points of Student’s t-
distribution. Next, for the general case where there are p treatments and a control, we write
z =
X1 −X0 − (mi −m0)√
1
Ni
+ 1
N0
. (1.17)
The lower confidence limits with joint confidence coefficient P for the p treatment effectsmi−m0
will be given by
(X1 −X0)− d′s
√
1
N1
+
1
N0
; (i = 1, 2, · · · , p)
if the p constants d′i are all chosen so that
Prob(t1 < d1
′, t1 < d2
′, · · · , tp < dp′) = P. (1.18)
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Similarly, the upper confidence limits will be given by
(X i −X0) + di′′s
√
1
Ni
+
1
N0
(i = 1, 2, · · · , p).
And, the two-sided confidence limits will be given by
(X i −X0)± di′′s
√
1
Ni
+
1
N0
(i = 1, 2, · · · , p),
if the p constants di′′ are chosen to satisfy
Prob(|t1| < d1′′, |t2| < d2′′, · · · , |tp| < dp′′) = P. (1.19)
The correlation coefficient is given by
ρij = 1/
√
(
N0
Ni
+ 1)(
N0
Nj
+ 1).
Note that (1.16) can be written as
P = Prob(z1 < d1
′, z1 < d2
′, · · · , zp < dp′s),
=
∫ +∞
−∞
F (d′1s, d
′
2s, · · · , d′ps)p(s)ds,
(1.20)
where F (z1, z2, · · · , zp) is the multivariate normal c.d.f. of the zi and p(s) is the probability density
function of s. Similarly, (1.17) can be written as
P = Prob(|z1| < d1′′, |z2| < d2′′, · · · , |zp| < dp′′s),
=
∫ +∞
−∞
G(d1
′′s, d2
′′s, · · · , dp′′s)p(s)ds,
(1.21)
where G(z1, z2, · · · , zp) is the c.d.f. of the |zi|.
In an earlier paper, Roessler (1946) also considered the problem of comparing several treat-
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ments with a control. The goal in Roessler (1946) was to construct a modified t-table to compare
selected pairs and apply more stringent test of significance. However, Roessler (1946) assumed
that the p comparisons are independent. Suppose n treatments are being compared with a control
giving n differences. Roessler (1946) goal was to test if the largest ratio, t′, difference/standard
error, is significant. Using P to denote the probability that errors of random sampling would give
a single difference equal to or greater than some value d, and letting Pn be the probability that the
largrest of n differences would equal or exceed d. Then, (1−P ) is the probability that one random
difference should be less than d and (1 − Pn) is the probability that n differences should be less
than d. Then Roessler (1946) derived that
(1− P )n = 1− Pn.
Paulson (1952), the author investigated the statistical problem of comparing the “best” of k
categories when comparing k − 1 experimental categories with a standard or control. Paulson
(1952) constructed means of normal distribution with a common unknown variance and also with
binomial distribution.
Let Π1,Π2, · · · ,Πk be the k categories, Π1 represents the standard or control, while Π2,Π3, · · · ,Πk
represents k − 1 categories. The goal in Paulson (1952) was to classify these categories into two
groups: one consisting of the categories which are superior to Π1 and a second group consisting of
categories that are inferior to or at most equal to Π1.
Given a sample consisting of kn independent observations {xij} (i = 1, 2, · · · , k; j =
1, 2, · · · , n), where xij is the jth observation with category Πi, to devise a statistical procedure
for selecting one out of the k categories as best so that of none of the experimental categories
Π2,Π3, · · · ,Πk is actually “superior” to Π1, then the probability that Π1 is selected will be≥ 1−α.
The constant α might be considered as roughly analogous to the type I error in the Neyman-
Pearson theory of testing a hypothesis.
In the normal case with known variance, Paulson (1952) treats the problem when σ is assumed
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to be known priori. Let xi =
∑n
j=1 xij/n, x
∗ = max(x2, x3, · · · , xk), α1 = α/(k − 1), and for
any α(0 < α < 1) let να ne defined by the equation
1√
2pi
∫ ∞
να
e−
1
2
t2dt = α. (1.22)
Let Π∗ be the experimental category whose mean is x∗, and let λ be a constant whose value
will be determined in a moment. The following procedure is proposed for the selection of the best
category:
If x∗ − x1 ≥ λσ
√
2
n
, select Π∗;
If x∗ − x1 < λσ
√
2
n
, select Π1.
(1.23)
and the statistical procedure can be completed by determining λ. The greatest lower bound of the
probability that x∗ − x1 < λσ
√
2
n
, select Π1 will occur when m1 = m2 = · · · = mk. Then since
x∗ and x1 are independent, we have
P
{
x∗ − x1 < λσ
√
2
n
|m1 = m2 = · · · = mk
}
,
=
∫ ∞
−∞
e−
1
2
r2
√
2pi
∫ r+λ√2
−∞
(k − 1)e
− 1
2
z2
√
2pi
[ ∫ z
−∞
e−
1
2
t2
]k−2
dzdr,
=
∫ ∞
−∞
e−
1
2
r2
√
2pi
[ ∫ r+λ√2
−∞
e−
1
2
t2
√
2pi
dt
]k−1
dr.
(1.24)
The constant λ will therefore be given as the root of the equation:
1√
2pi
∫ ∞
−∞
e−
1
2
r2
[ 1√
2pi
∫ r+λ√2
−∞
e−
1
2
t2dt
]
dr = 1− α. (1.25)
and the values of λ is a function of α and k.
Gupta and Sobel (1958) described the procedure that controls the probability that the selected
subset contains all those populations better than the control for any possible true configuration. If
a correct decision is defined as a selected subset which contains all those populations better than
the standard, then the procedure given below guarantees a probability of a correct decision to be
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at least P ∗, not only when the k − 1 populations are equal to (or worse than ) the standard, but for
any possible true configuration.
Assume that populations Π1,Π2, · · · ,Πp with unknown means µ1, µ2, · · · , µp, respectively are
given and that Π0 is the standard or control, whose mean µ0 may or may not be known. So Gupta
and Sobel (1958) discussed the various cases separately, as described below:
Case A: For common known variance (µ0 known) For each of the p populations Πi( i =
1, 2, · · · , p), ni independent observations are taken. Let xi denote the sample mean from Πi and
let σ2 be the common known variance. The procedure to selected the subset is
xi ≥ µ0 − dσ/√ni.
Let p1, p2 denote the true number of populations with µ ≥ µ0 and µ < µ0, so the probability P
of retaining all the p1 populations with µ ≥ µ0 is given by
P =
p1∏
i=1
P
{
x′i ≥ µ0 − dσ/
√
n′i
}
,
=
p1∏
i=1
P
{√
n′i(x
′
i − µ′i) ≥ −d+
√
n′i(µ0 − µ′i)/σ
}
.
(1.26)
Case B: For common known variance (µ0 unknown) In this case n0 independent observations
are taken on the standard Π0. Let x0 denote the mean of these n0 observations and let σ2 be the
known common variance for all the (p + 1) populations. Then the procedure to select all those
population is
xi ≥ x0 − dσ/√ni. (1.27)
Letting f(x) denote the standard normal density, the equation to determine d is then:
∫ ∞
−∞
p∏
i=1
[
F (µ
√
ni
n0
+ d)
]
f(µ)dµ = P ∗. (1.28)
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For the special case ni = n(i = 0, 1, · · · , p) this reduces to
∫ ∞
−∞
F p(µ+ d)f(µ)dµ = P ∗. (1.29)
In more general case when the populations have different but known variances the procedure
is defined by
xi ≥ x0 − dσi/√ni. (1.30)
And the value of d is determined by the equation:
∫ ∞
−∞
p∏
i=1
[
F (µ
σ0
σi
√
ni
n0
+ d)
]
f(µ)dµ = P ∗. (1.31)
Above simplified to (1.28) when σi/
√
ni = constant (i = 0, 1, · · · , p).
Case C: For common unknown variance (µ0 known), as in Case A, ni observations are taken
only on the p population
∏
i, (i = 1, 2, · · · , p). Let S2ν denote the pooled estimate of σ2. Then the
procedure to select those and only those populations Πi is:
xi ≥ µ0 − dsν/√ni. (1.32)
The equation determining d is
∫ ∞
0
F p(yd)qν(y)dy = P
∗, (1.33)
where qν(y) is the density of y = sν/σ = χν/
√
ν.
Case D: For common unknown variance (µ0 unknown) In this case ni observations are taken
on all the population Πi(i = 0, 1, · · · , p). The inequality defining the procedure is
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xi ≥ x0 − dsν/√ni. (1.34)
The equation determining d is
∫ ∞
0
∫ ∞
−∞
[ p∏
i=1
F (µ
√
ni
n0
+ yd)
]
f(µ)qν(y)dµdy = P
∗. (1.35)
For ni = n(i = 0, 1, · · · , p) this reduces to
∫ ∞
0
∫ ∞
−∞
F p(µ+ yd)f(µ)qν(y)dµdy = P
∗. (1.36)
Paulson (1964) investigated a sequential procedure for selecting the normal population with
the greatest mean when the k population have a common known variance or the k population have
a common but unknown variance, and, the probability of making the correct decision for each case
is calculated and be controlled at some preassigned level when the largest mean exceeds all the
other means by at least a specific amount. The best category is defined as the category with the
largest population mean.
The k categories or populations are denoted by pi1, pi2, · · · , pik. LetXis denote the sthmeasure-
ment with category pii(i = 1, 2, · · · , kands = 1, 2, · · · ). Xis is be assumed normally distributed
with mean mis and variance σ2, and the measurement {Xis} are independent random variables for
all values of i and s. Assume that µ1, µ2, · · · , µk are unknown parameters and the best category is
the one with the largest µ, and
µ[1] ≤ µ[2] ≤ µ[3], · · · ,≤ µ[k].
The purpose of Paulson (1964) is to investigate a sequential procedure for selecting the best
category that when µ[k] − µ[k−1] ≥ ∆ the probability of making the correct decision and selecting
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pi[k] is ≥ 1− α.
For the case of a common known variance, Paulson (1964) first specifying a class Sλ of se-
quential procedures, and then show that for each value of λ the corresponding sequential proce-
dure has the required property that P [pi[k] is selected | µ[k] − µ[k−1] ≥ ∆ ≥ 1 − α. Then at
the first stage Paulson (1964) take one measurement with each category, obtaining measurements
(X11, X21, · · · , Xk1). Then eliminate from further consideration any category pij for which
Xj1 < max{X11, X21, · · · , Xk1} − aλ + λ,
where aλ = [σ2/(∆− λ)]log((k − 1)/α).
If all but one category are eliminated after the first stage, the procedure stops and select the
remaining category as the best one. Otherwise the procedure goes on to the second stage and
take one measurement on each category not eliminated after the first stage. At the rth stage of
the experiment (r = 2, 3, · · · ,Wλ) the procedure take one measurement on each category not
eliminated after the (r − 1) stage, and then eliminate any remaining category pij for which
Σrs=1Xjs < maxν{Σrs=1Xνs} − aλ + λ.
Then let δ2 denote the parameter configuration µ[k] ≥ µ[k−1] + ∆, and let δ∗2 denote the pa-
rameter configuration µk ≥ µj + ∆ for j = 1, 2, · · · , k − 1. And Paulson (1964) derived that
P [pik is selected | δ∗2] ≥ 1 − α. And it is obvious from the symmetry of the sequential procedure
that it is sufficient to prove that the probability of a correct decision is ≥ 1− α when [k] = k. So
by symmetry P [pik is selected | δ2] ≥ 1− α.
For the case of a common but unknown variance. Paulson(1964) start by taking a sample
of n0 measurements with each category. Let X i. =
∑n0
s=1Xis/n0, X .s =
∑k
i=1Xis/k, X =∑k
i=1
∑n0
s=1Xis/kn0. Under situation A, let s
2 =
∑k
i=1
∑n0
s=1(Xis − Xi.)2/k(n0 − 1) be the
usual estimate of σ2 with f = k(n0 − 1) degrees of freedom, while under situation B let s2 =
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∑k
i=1
∑n0
s=1(Xis−X i.−X .s+X)2/(k−1)(n0−1) be the estimate of σ2 with f = (k−1)(n0−1)
degrees of freedom, so that in each situation fs2/σ2 has the χ2 distribution with f degree of
freedom. Let
g = [((k − 1)/α)2/f − 1]f/2, (1.37)
let a∗ = 4s2g/3∆, and let W ∗ denote the largest integer less than 4a∗/∆.
Having obtained n0 measurement with each category, we compute s2 and the values of g, a∗,
and W ∗. If n0 > W ∗ the procedure stop and select the category with the largest cumulative sum.
If n0 ≤ W ∗, then the procedure eliminate any category pij for which
n0∑
s=1
Xjs < max{
n0∑
s=1
Xνs} − a∗ + n0∆/4, (1.38)
where the max is taken over all k categories.And Paulson (1964) verified that
P [pik is not selected | δ∗2] ≤ α.
Tong (1969) derived a single-stage procedure to solve the problem for σ2 known case. The decision
rule used is based on the differences of the sample means:
SB = {Πi : X¯i − X¯0 < d, i = 1, · · · , k},
SG = {Πi : X¯i − X¯0 > d, i = 1, · · · , k}.
(1.39)
where X¯i = N−10 Σ
N0
j=1Xij . Let us define
d = (δ∗1 + δ
∗
2)/2, a = (−δ∗1 + δ∗2)/2, λ = σ/a, and,
m =
 k/2 if k is even;(k + 1)/2 if k is odd.
(1.40)
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Then Tong(1969) derived
P
[
CD|µ0(r), σ2, R1
]
=
( 1
2
N0)
1
2 /λ∫
−∞
· · ·
( 1
2
N0)
1
2 /λ∫
−∞
(2pi)−
k
2 |Σ|− 12 exp(−1
2
Y ′Σ−1Y )
k∏
i=1
dyi, (1.41)
with the(k X k)covariance matrix Σ as:
Σ =

1 1
2
−1
2
· · · −1
2
. . . ... . . .
...
1
2
1 −1
2
· · · −1
2
−1
2
· · · −1
2
1 1
2
... . . .
... . . .
−1
2
· · · −1
2
1
2
1

. (1.42)
For every λ and every N0,the LF configuration under R1 is given by µ01 = µ
0
2 = · · · = µ0m =
µ0 + δ
∗
1, µ
0
m+1 = µ
0
m+2 = · · · = µ0k = µ0 + δ∗2 . Next, let b = b(P ∗, k) be the solution of the
equation
P ∗ =
b∫
−∞
· · ·
b∫
−∞
((2pi)−
k
2 |Σ|− 12 exp(−1
2
Y ′Σ−1Y )
k∏
i=1
dyi. (1.43)
Then if the sample size N0 is the smallest integer satisfying
N0 ≥ 2λ2b2 (1.44)
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then it satisfied the probability requirement that
P
[
CD|µ0(r), σ2, R
]
≥ P ∗ for every mean vector µ. (1.45)
The value of b have been given in Table 1 of Tong (1969). For unknown σ2 case, Tong (1969)
formulated two-stage and purely sequential procedures.
1.4 Selection and Ranking For Two Parameter Exponential
Suppose that we have k(≥ 2) independent and exponentially population pi1, . . . , pik, with density
function of pii, i = 1, 2, · · · , k given by
fX(x) = σ
−1exp{−(x− θi)/σ}I(x > θi). (1.46)
The parameter θi is usually called the guarantee time. The parameter σ is the standard deviation
of the distribution. It is tacitly assumed that the variance for all the distributions is the same. Let
θ[1] ≤ θ[2] ≤ · · · ≤ θ[k] be the ordered values of the unknown guarantee time. It is not known which
population is associated with θ[i] (i = 1, 2, ..., k). The best population is the population associated
with θ[k]. The best population can also be seemed as the one associated with the largest mean.
Then given a pre-assigned constant P ∗, 2−k < P ∗ < 1, and letting CD denotes correct decision of
selecting the best k populations, we seek statistical methodologies ℘ to determine that
P{CD|θ, σ2, ℘} ≥ P ∗ ∀ θ ∈ Rk+1, σ ∈ R+. (1.47)
For the know σ2 case, Raghavachari and Starr (1970) used single stage procedure to solve
the problem assuming that θ in (1.46) is 1. Let µ[1] ≥ µ[2] ≥ ldotsµ[k] denote the ordered µ-
values,Raghavachari and Starr (1970)want to select the t populations for with µ ≥ µ[t] with proba-
bility at P ∗ whenever µ[t]−µ[t+1] ≥ δ; P ∗ annd δ are preassigned constants, with
(
k
bt
)−1
< P ∗ < 1
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and δ > 0.
The goal of Raghavachari and Starr (1970) is to find a procedure for which
Pω[CSt] ≥ P ∗ for all ω  Ωt, (1.48)
where letting CSt denote correct selection of the best t populations and letting Ωt be the set of
all vectors ω = (µ1, . . . , µk) with µ[t] − µ[t+1] ≥ δ.
Then Raghavachari and Starr (1970) obtained a closed expression for the probability of correct
selection computed under the least favorable configuration of the parameters and use this expres-
sion to determine the size of the sample necessary to accomplish (1.48) for both exponential and
Uniform cases.
In exponential case, for a fixed number n of independent observations on each of the k random
variables and denote by x˜j = x˜j(n) the minimum of the n observations on xj, j = 1, · · · , k.
Denote the ordered x˜-values by x˜[1] ≥ x˜[2] ≥ · · · ≥ x˜[k], and
select t population for which x˜ ≥ x˜[t]. (E)
Then they derived that for any ω  Ω∗t , with fixed µt = µ0 + δ,
Pω[CSt] = Pω[min(x˜1, . . . , x˜t) ≥ max(x˜t+1, . . . , x˜k)]
= Pω[
k⋂
j=k+1
(x˜j ≤ min(x˜1, . . . , x˜t))]
=
∞∫
µt
k∏
j=t+1
Pµj [x˜j ≤ ω]h(ω;µ1, µ2, . . . , µt)dω
≥
∞∫
µ0+δ
Pµ0 [xj ≤ ω]h(ω;µ0 + δ, µ0 + δ, . . . , µ0 + δ)dω
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= Pω0 [min(x˜1, . . . , x˜t) ≥ max(x˜t+1, . . . , x˜k)]
= Pω0 [CSt].
So that for any ω∗  Ω∗t
Pω∗ [CSt] = Pω0 [CSt]. (1.49)
where ω∗ ⊂ ω and ω∗ = (µ1, . . . , µk) and we shall see that Pω0 [CSt] does not depend on the value
of µ0. In order to find the sample size necessary to accomplish the goal (1.48), a closed expression
for Pω0 [CSt] with µ0 fixed was computed:
Pω0 [CSt] = (I − e−nδ)k−t + (k − t)entδI(e−nδ, t+ I, k − t). (1.50)
and the chosen of sample size n satisfied:
n δ ≥ − log ν, (1.51)
where ν is the solution of the equation:
(I − ν)k−t + (k − t)ν−tI(ν, t+ I, k − t) = P ∗, (1.52)
with ν = e−nδ.
In a Uniform distribution case, for a fixed number n of independent observations on each of
the k random variables and denote by y˜j = y˜j(n) the minimum of the n observations on yj, j =
1, · · · , k. Denote the ordered y˜-values by y˜[1] ≥ y˜[2] ≥ · · · ≥ y˜[k], and
select s population with y˜ ≥ y˜[k−s+1]. (U)
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Raghavachari and Starr (1970) indicates that the problem of finding a procedure (U) when we
wish to select the best s populations in the uniform case is identical to the corresponding problem
(1.48) when we wish to select the best k-s populations in the exponential case.
Pω′∗ [CS
′
s] = Pω∗ [CSk−s], (1.53)
for any ω′∗  Ω′∗s , ω
∗  Ω∗k−s.
For σ unknown, Desu et al. (1977) considered a two-stage procedure for selecting the best popu-
lation.The probability of correct selection is given by
P (CS) = P{Y (k) ≥ Y (i); (i = 1, 2, · · · , k − 1)},
where Y (i) is associated with Y [i]. Let dki = Y[k]− Y[i] (i = 1, 2, · · · , k − 1).
Now
P (CS) = P{Zk +Ndki/θ ≥ Zi; (i = 1, 2, · · · , k − 1)},
where Zi = N(Y (i)− Y [i])/θ. Since dki ≥ d,
P (CS) ≥ P{Zk +Nd/θ ≥ Zi; (i = 1, 2, · · · , k − 1)}
= P{Zi/T ≤ (Zk + Nd
θ
)/T ; (i = 1, 2, · · · , k − 1)},
where T = 2k(n0− 1)θˆ/θ has a chi-square distribution with 2k(n0− 1) degrees of freedom. Then
as Nd/(θT ) ≥ h , the requirement on the P (CS) can be met, by choosing h such that
P (CS) = P{Zi ≤ Zk + hT ; (i = 1, 2, · · · , k − 1)} = P ∗. (1.54)
Since Zi has the density f(z; 0, 1), then (1.54) can be written as:
23
∞∫
0
{
∞∫
0
(1− e−z−ht)k−1e−zdz}g(t)dt = P ∗.
where g(t) is the probability density function of T. Expanding (1− e−z−ht)k−1 as finite series and
carrying out the term by term integration, obtained that
K∑
J=1
(−1)J+1(k − 1)!/{[J !(K − J)!][1 + 2h(J − 1)ξ]} = P ∗.
Values of h that satisfy this equation, for P ∗ = 0.95 and several values of k and n0 are given in
the Table of Desu et al. (1977). Mukhopadhyay (1986) considered a sequential procedure to select
the population associated with the largest location parameter for negative exponential distributed
population with equal but unknown scale parameter σ.
Letting µ[1] ≤ µ[2] ≤ . . . ≤ µ[k] be the ordered values of the location parameters. The problem
is to find the “best” population which is defined as the one associated with the location param-
eter µ[k]. Under least favorable configuration (LFC), which is µ[1] = · · · = µ[k−1] = µ[k] − δ∗,
Mukhopadhyay (1986)studied sequential selection procedure to achieve the objective
P (CS) ≥ P ∗ whenever θ  Ω(δ∗)
and also studied some second order asymptotic (as δ∗ → 0) properties of a sequential proce-
dure.
Let {Xij : j = 1, 2, · · · } be a sequence of independence and identically distributed random
variables from Πi, i = 1, · · · , k., and write X˜in as the sample minimum from the population
Π(i), i = 1, · · · , k. Then,
P [CS] = P [X˜kn ≥ X˜in, i = 1, · · · , k − 1]
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= P [Zkn + δinσ
−1 > Zin], (1.55)
where δt = µ[k] − µ[i], Zin = n{X˜in − µ[i]/σ}. Then when δt = δ∗, the infP (CS) will be at least
P ∗ provided that n is chosen as the smallest integer ≥ C = aσ/δ where a satisfies the equation:
∞∫
0
{1− exp(−z − a)k−1exp(−z)dz} = P ∗. (1.56)
For given values of k and P ∗, the corresponding values of a satisfying (1.56) can be obtained
from Raghavachari and Starr (1970). In the sequential procedure, Mukhopadhyay (1986) propose
the stopping time
N = inf{n ≥ m0 : n ≥ aWn/δ∗}, (1.57)
where “a” from (1.56) and m0(≥ 2) is the starting sample size from each population. Now we
have,
P [CS] = P [X˜kn ≥ X˜in, i = 1, · · · , k − 1]
= P [Zkn + δiNσ
−1 > Zin, i = 1, · · · , k − 1]
=
∑
m0<n<∞
P{Zkn + δiNσ−1 > Zin, i = 1, · · · , k − 1}P (N = n)
= E
[ ∞∫
0
{1− exp(−z −Nδ∗σ−1)k−1exp(−z)dz}
]
. (1.58)
Applying the techniques of Swanepoel and vanWyk’s (1982) Lemma 1, Mukhopadhyay (1986)
derives a random variable M which has the same probability distribution as of random variable N
defined by (1.57).
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M = inf{m ≥ m0 :
m−1∑
i=1
Yi ≤ δ∗m(m− 1)/a}, (1.59)
where Y1, Y2, · · · are iid with the pdf:
gY (y) = (k/σ)
k{(k − 1)!}−1yk−1exp(−ky/σ)I(y > 0). (1.60)
However, purely sequential sampling from each population one at a time. So to the concern of
the amount of sampling operation, Mukhopadhyay and Solanky (1991) proposed to implement the
accelerated sequential procedure to terminate the sequential procedure ‘early’ in the process.
For independent and identically distributed (i.i.d) random variablesXi1, . . . , Xin from the pop-
ulation Πi, Mukhopadhyay and Solanky (1991) write
X˜in = min{Xi1, . . . , Xin}, Win = (n− 1)−1
n∑
j=1
(Xij − X˜in),
and
Wn = n(kn− k)−1
k∑
i=1
Win,
for i = 1, . . . , k, n ≥ 2. We estimate µi by X˜in and σ by Wn. And the stopping rule:
L = L(δ∗) = inf{n ≥ m1 : n ≥ aWn/δ∗}
where m1(≥ 2) is the starting sample size and a is the solution of the equation:
∞∫
0
(1− exp(−z − a))k−1exp−zdz = P ∗.
for given valuses of k and P ∗, the value of a can be obtained from Desu and Sobel (1968), and
Raghavachari and Starr (1970).Then if σ known, the infimum of P (CS) will be at least P ∗ provid-
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ed that sample size n should be selected from each population and select the population associated
with the largrst X˜in where n ≥ C = aσ/δ∗.
Let 〈x〉for the largest integer < x, then the accelerated sequential procedure stoppping time
can be write as :
t = t(δ∗) = inf{n ≥ m1 : n ≥ %aWn/δ∗}, (1.61)
N1 = N1(δ
∗) = 〈aWtδ∗−1 + q〉+ 1, (1.62)
N = N(δ∗) = max{t(δ∗), N1(δ∗)} ξ→ N(0, (k%)−1). (1.63)
Mukhopadhyay and Solanky (1991) derived the first-order results, for the accelerated stopping
time N(δ∗), as δ∗ → 0:
(i) N(δ∗)/C → 1 a.s.;
(ii) E{N(δ∗)/C} → 1;
(iii) C−1/2{N(δ∗)− C}.
The details of above are avaiable in Mukhopadhyay and Solanky (1991).
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Chapter 2
Multistage Methodologies for Partitioning a Set of Exponential
Populations
The problem of comparisons with a control has been an active research area for over seven decades.
The desire of the experimenter to have the best population to be some “specified amount better”
than what is already in use has motivated the research in this area. This problem has been studied by
many and under different formulations. Tong (1969) formulated the partition problem using Bech-
hofer’s (1954) indifference zone formulation and constructed a two-stage and a purely sequential
procedure. Among slightly different formulations of this problem is the problem of selection of
the best treatment relative to a control population or selecting a subset of the treatments having
means greater than that of a control. For more on such related formulations one is recommended
Bechhofer, Santner and Goldsman (1995). For a general overview of sequential methodology and
of the partition problem, the reader is recommended Ghosh, Mukhopadhyay and Sen (1997), and,
Mukhopadhyay and Solanky (1994).
Suppose that we have pi0, pi1, . . . , pik, independent and exponentially distributed populations,
with density function of pii, i = 0, 1, · · · , k given by
fX(x) = σ
−1exp{−(x− θi)/σ}I(x > θi). (2.1)
Assume that the location parameters θi, i = 0, 1, · · · , k and the common scale parameter σ are
all unknown. We refer to pi0 as the control population. The goal is to partition the set of treatments
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Ω = (pii : i = 1, 2, · · · , k), into two disjoint and exhaustive subsets, corresponding to “Good” and
“Bad” populations compared to the control population with a pre specified probability of correct
partition. Given arbitrary but fixed constants δ1 and δ2, δ1 < δ2, we define three subsets of Ω along
the lines of Bechhofer’s (1954) indifference-zone formulation, as:
ΩL = {pii : θi ≤ θ0 + δ1, i = 1, · · · , k},
ΩM = {pii : θ0 + δ1 < θi < θ0 + δ2, i = 1, · · · , k},
ΩR = {pii : θi ≥ θ0 + δ2, i = 1, · · · , k}.
(2.2)
We refer to ΩR as the set of “good populations” and ΩL as the set of “bad populations”. The
set ΩM would be referred to as the set of “mediocre populations”. Adopting the Bechhofer’s
indifference zone approach, we are interested in the correct partition of the populations in ΩR and
ΩL. And, we will be indifferent to partition of populations in ΩM . That is, with high accuracy we
want to partition the set Ω into two disjoint subsets PL and PR, such that, ΩL ⊆ PL and ΩR ⊆ PR.
Such a partition is known in the literature as a correct decision (CD). In other words, given a pre
assigned number P ∗, 2−k < P ∗ < 1, we seek statistical methodologies ℘ to determine PL and PR,
such that
P{CD|θ, σ2, ℘} ≥ P ∗ ∀ θ ∈ Rk+1, σ ∈ R+. (2.3)
We will use the following notation in the rest of this paper for convenience:
d = (δ1 + δ2)/2, a = (−δ1 + δ2)/2, λ = σ/a, and,
r =
 k/2 if k is even;(k + 1)/2 if k is odd.
(2.4)
For normal populations case, Tong (1969) gave a single-stage procedure for the partition prob-
lem when the common variance known. The single-stage procedure provided above is an extension
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of Tong’s (1969) single-stage procedure. For normal populations case when the common variance
is unknown, Tong (1969) constructed a two-stage and a purely sequential procedure. Datta and
Mukhopadhyay (1998) studied this problem further and constructed a fine-tuned purely sequential
procedure and some other multistage methodologies, emphasizing the second-order asymptotics.
Solanky (2001) has constructed an elimination type procedure for the normal populations partition
problem which takes samples of unequal sizes. The reader is also recommended to look at Chen
and Rollin (2004), Aoshima and Takada (2000), and Solanky (2006), who have studied various
aspects of the partition problem. Many other additional references to the partition problem are
available in the articles mentioned in this paragraph.
2.1 A Single-Stage Procedure
We assume that we observe random variables X0j, X1j, · · · , Xkj from pi0, pi1, · · · , pik, j =
1, · · · , n, respectively, in a sequential framework, where n is to be determined below. Assum-
ing that σ is known, we denote
Ti = min1≤j≤n(Xij), i = 0, 1, · · · , n. (2.5)
where Ti is the minimum order statistic. The first order statistic (or smallest order statistic) is
always the minimum of the sample, that is,
T1 = min{X11, X12, · · · , X1n}
and,
Tn = min{Xn1, Xn2, · · · , Xnn}
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Then let us find the probability of Ti:
P (X1 > x) =
n∏
i=1
P (Xi > x) =
n∏
i=1
[1− F (x)] = [1− F (x)]n
FX1(x) = 1− [1− F (x)]n
fX1(x) = n[1− F (x)]n−1f(x),
since f(x) = 1
σ
e
−(x−θi)
σ for x > θi then
FX1(x) =
∫ x
0
f(x)dx =
∫ x
0
1
σ
· e−(x−θi)σ dµ = 1− e−λx
fX1(x) = n[1− F (x)]n−1f(x) =
n
σ
· e−n(x−θi)σ , (x > θi).
Thus the probability density function of T1 is
fT1(t) =
n
σ
· e−n(x−θi)σ , (x > θi).
Along the lines of Desu et al. (1977), we define a pooled estimator of σ as
σˆ = Σki=0Σ
n
j=1(Xij − Ti)/((k + 1)(n− 1)). (2.6)
Note that 2(k + 1)(n − 1)σˆ/σ is independent of Ti and has a chi-squared distribution with 2(k +
1)(n− 1) degrees of freedom. Next, we Consider the decision rule ℘ defined as:
PL = {pii : Ti − T0 < d, i = 1, · · · , k},
PR = {pii : Ti − T0 > d, i = 1, · · · , k}.
(2.7)
Next, we will consider a parametric configuration which is most unfavorable for the partition
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problem on hand. Such parametric configuration is known as the least favorable configuration
(LFC) in the statistical literature. It is clear that for a mean vector to be a LFC under the procedure
(2.2), the set ΩM must be empty, and all the populations in ΩL and ΩR must have common means
θ0 + δ1 and θ0 + δ2, respectively.
Theorem 1 Assuming σ2 is known, the partition problem (2.2) has
P
[
CD|θ0(r′), σ, ℘
]
≥ P ∗ (2.8)
for the partition rule (2.7) provided that the sample size is that n∗ = bσ
a
. The constant b = b(k, P ∗)
is the solution of an integral equation (2.13).
Proof. Let θ0(r′) be the configuration such that θi = µ0 + δ2 and θj = µ0 + δ1, 0 < i ≤ r′,
r′ < j ≤ k for some r′ such that 0 < r′ ≤ k. Then, we have
P
[
CD|θ0(r′), σ, ℘
]
≥ P
[
Tj − T0 < d, Ti − T0 > d, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Tj − T0 − θj + θ0 < d− θj + θ0, Ti − T0 − θi + θ0 > d− θi + θ0, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
(Tj−T0−θj+θ0)
σ/n
<
d−θj+θ0
σ/n
, Ti−T0−θi+θ0
σ/n
> d−θi+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Tj−θj
σ/n
− T0−θ0
σ/n
<
d−θj+θ0
σ/n
, Ti−θi
σ/n
− T0−θ0
σ/n
> d−θi+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
.
(2.9)
Next, we write Yj =
Tj−θj
σ/n
, r′ < j ≤ k, Yi = Ti−θiσ/n , 0 < i ≤ r′, Y0 = T0−θ0σ/n .
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Let us first find the distribution of Yi, (or Yj or Y0) as defined above:
F (Y ) = P (
Ti − θi
σ/n
≤ y)
= P (Ti ≤ yσ
n
+ θi)
=
∫ θi+ yσn
θ
n
σ
· e−n(y−θi)σ dy
= −enθσ ·
∫ θi+ yσn
θ
e
(−ny)
σ d (−ny)
σ
= −e−y + enθiσ −θi
That is f(y) = F (Y )′ = e(−y), which is a standard exponential distribution. Hence that Yi, Yj
and Y0, 0 < i ≤ r′, r′ < j ≤ k all have standard exponential distributions.Note that for r′ < j ≤ k,
d−θj+θ0
σ/n
≤ d−δ1
σ/n
, and for 0 < i ≤ r′, d−θi+θ0
σ/n
≥ d−δ2
σ/n
. Next using the notations from (2.4), we have
P
[
CD|θ0(r′), σ, ℘
]
≥ P
[
Tj − T0 < d, Ti − T0 > d, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Tj − T0 − θj + θ0 < d− θj + θ0, Ti − T0 − θi + θ0 > d− θi + θ0,
]
≥ P
[
(Tj−T0−θj+θ0)
σ/n
<
d−θj+θ0
σ/n
, Ti−T0−θi+θ0
σ/n
> d−θi+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Tj−θj
σ/n
− T0−θ0
σ/n
<
d−θj+θ0
σ/n
, Ti−θi
σ/n
− T0−θ0
σ/n
> d−θi+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Yj − Y0 <
δ1+δ2
2
−θj+θ0
σ/n
, Y0 − Yi <
δ1+δ2
2
−θj+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Yj − Y0 <
δ1
2
+
δ2
2
−θ0−δ0+θ0
σ/n
, Y0 − Yi <
δ1+δ2
2
−θj+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Yj − Y0 <
δ2−δ1
2
σ/n
, Y0 − Yi <
δ1+δ2
2
−θj+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Yj − Y0 < anσ , Y0 − Yi < anσ , 0 < i ≤ r′, r′ < j ≤ k
]
.
(2.10)
Let the (k × k) covariance matrix Σr′ = (σij) be given by
σij =

2 for i = j,
1 for i 6= j, and, 0 < i, j ≤ r′ or r′ < i, j ≤ k,
−1 for 0 < i ≤ r′, and, r′ < j ≤ k.
(2.11)
33
Let us define zj = Yj−Y0 for r′ < j ≤ k and zi = Y0−Yi for 0 < i ≤ r′. The density distribution
for Z ′ = (z1, ..., zk) is:
f(z′) = 2(2pi)−
k
2 |Σ|− 12 (ZΣ−1Z ′/2)ν/2Kν(
√
2ZΣ−1Z ′) (2.12)
whereKν(.) is the modified Bessel function of the third kind given byKν(u) = 12
u
2
ν
∞∫
0
t−ν−1exp(−t−
u2
4t
dt, u > 0. Note that the vector Z ′ = (z1, ..., zk) has a symmetric multivariate Laplace distribu-
tion with mean vector zero and the covariance matrix Σr′ as defined above.
Note that (2.10) gives the infimum of the probability of correct decision under ℘ for the set of
all configurations such that there are r′ populations in ΩR and k−r′ in ΩL. Next, along the lines of
Tong (1969) Lemma 1.1 , we derive the Least Favorable Configuration (LFC) under the decision
rule ℘ as: µ1 = · · · = µr = µ0 + δ2, and, µr+1 = · · · = µk = µ0 + δ1, where r is defined in (2.4).
We will refer to the LFC as θ0. Next, along the lines of (2.11) with r in place of r′, we define the
covariance matrix Σ as:
Σ =

2 for i = j,
1 for i 6= j, and, 0 < i, j ≤ r or r < i, j ≤ k,
−1 for 0 < i ≤ r, and, r < j ≤ k.
Next, let b = b(P ∗, k) be the solution of the equation
P ∗ =
b∫
−∞
· · ·
b∫
−∞
2(2pi)−
k
2 |Σ|− 12 (ZΣ−1Z ′/2)ν/2Kν(
√
2ZΣ−1Z ′)
k∏
i=1
dzi,
where ν = (2−k)/2 and Kν(.) is the modified Bessel function of the third kind given by Kν(u) =
1
2
u
2
ν
∞∫
0
t−ν−1exp(−t− u2
4t
dt, u > 0. Then, one can immediately note that
P
[
CD|θ, σ, ℘
]
≥ P ∗,
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provided n satisfies
n ≥ bσ
a
(= n∗, say).
then the probability requirement (2.3) is satisfied. This complete the proof of Theorem 1. 
Remark 1 The solution b = b(k, P ∗) of (2.14) is the equi-coordinate percentage point of a k-
dimensional multivariate Laplace distribution with the covariance matrix Σr described above. k
is the total number of populations. The values of the constant b satisfying the equation (2.13) were
calculated by Monte-Carlo integration and Bisenction method, and are proved in table 2.1.
k
P ∗
0.50 0.75 0.90 0.95 0.975 0.99
1 0.0012 0.6934 1.6016 2.3047 2.9688 4.0625
2 0.6250 1.3623 2.3047 2.9688 3.6719 4.5315
3 0.8496 1.6211 2.5879 3.2814 4.0625 4.9219
4 1.0425 1.8481 2.8516 3.5938 4.1406 5.2344
5 1.2103 2.1240 2.9883 3.6682 4.4336 5.0769
6 1.4209 2.5761 3.1201 3.9483 4.8065 5.0403
7 1.8536 2.5981 3.2567 4.3225 4.9216 5.7611
8 1.9832 2.8273 3.6035 4.6631 4.9792 5.3125
9 1.9987 2.9162 3.2030 4.3066 7.4707 6.5505
10 2.0278 3.1293 3.7500 4.8010 7.6710 8.1615
11 2.3216 3.2756 3.9021 5.0212 7.5761 8.9278
12 2.4562 3.6921 4.6091 4.3695 7.6172 9.8433
14 2.6721 3.8678 4.6821 6.2012 8.0856 9.9590
16 2.9867 4.1267 4.9799 8.7387 7.499 9.9609
18 3.3212 4.3629 4.8434 9.9582 9.9907 9.9953
Table 2.1: Equi-coordinate percentage points of b of a multivariate exponential distribution
For the Bivariate Laplace case, the covariance is given below:
Σzz′ =
 σ21 σ1σ2ρ
σ1σ2ρ σ
2
2
 . (2.13)
where σ1 =
√
2, σ2 =
√
2, and ρ = −1
2
. The density function for bivariate Laplace is:
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f(z1z2) =
1
piσ1σ2
√
1− ρ2K0
(√2(z21/σ21 − 2ρz1z2/(σ1σ2) + z22/σ22)
1− ρ2
)
(2.14)
The simulated graph for the bivariate pdf is given in Figure (2.1):
Figure 2.1: Probability density function for bivariate Laplace Distribution
For details on Multivariate Laplace Distribution one may look at Kotz et al. (2001).
The single-stage procedure is with σ known, and one collects a sample of size n∗ from each of
pi0, pi1, . . . , pik, and, uses the decision rule ℘ given by (2.7) to partition the k populations, then the
probability requirement (2.3) is achieved. However, if σ is unknown, then there does not exist a
single-stage procedure which can achieve the probability requirement (2.3). For general details on
non-existence of a single-stage procedure, one may refer to Dudewicz (1971).
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2.2 Monte-Carlo Simulation
In this section the single-stage procedure (2.14) is simulated via Monte Carlo simulations to study
the performance of the procedure. The procedure is simulated under various parametric configu-
rations in order to verify the LFC. Recall that the single-stage procedure assumes σ2 is known. In
order to compute the value of n∗, the value of the design constant b is obtained from the Table 2.1
for the given value of k and the target value of the probability of correct decision P ∗.
Table 2.2 - 2.7 lists the samples of size n∗ = 25, 50, 100, 200, 400, and 800 and itersize =
2000, 5000, and 10000. As we know that the more large the itersize, the more stable the simulation
result is. One note that the mean of P value are all greater than 0.95 in each n∗ and itersize table,
meaning the good performance of the result we derived in (2.14).
In Table 2.2, we have summarized the performance of the single-stage procedure under various
parametric configurations for the case when k = 4. Note that the configuration (2, 2) is the
Least favorable Configuration under which there are all equal number of treatments on the
two boundaries as discussed before. And, the other parametric configurations summarized in the
Table 2.2 are (3, 1), (1, 3), (4, 0), and (0, 4).
The findings in the Table 2.2 confirm the theoretical results derived in the Theorem 1 that the
generalized partition procedure satisfies the probability requirement (2.10) for all the parametric
configurations. And, one will also note that the estimated value of the probability of the correct
decision is least for the parametric configuration (2,2). Which verifies that this is the parametric
configuration for which the P (CD) is least among all parametric configurations.
Table 2.8 - 2.12 lists the samples of size n∗ = 25, 50, 100, 200, 400, and 800 and itersize =
2000, 5000, and 10000. As we know that the more large the itersize, the more stable the simulation
result is. One note that the mean of P value are all greater than 0.95 in each n∗ and itersize table,
meaning the good performance of the result we derived in (2.14).
In Table 2.8, we have summarized the performance of the single-stage procedure under various
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 2, 2) 25 0.9625 0.0042 0.1438 0.1438 1
( 3, 1) 25 0.9660 0.0051 0.1438 0.1438 1
( 1, 3) 25 0.9685 0.0039 0.1438 0.1438 1
( 0, 4) 25 0.9800 0.0031 0.1438 0.1438 1
( 4, 0) 25 0.9515 0.0048 0.1438 0.1438 1
( 2, 2) 25 0.9505 0.0049 0.2875 0.2875 2
( 3, 1) 25 0.9505 0.0048 0.2875 0.2875 2
( 1, 3) 25 0.9610 0.0043 0.2875 0.2875 2
( 0, 4) 25 0.9750 0.0035 0.2875 0.2875 2
( 4, 0) 25 0.9560 0.0046 0.2875 0.2875 2
( 2, 2) 25 0.9554 0.0029 0.1438 0.1438 1
( 3, 1) 25 0.9588 0.0026 0.1438 0.1438 1
( 1, 3) 25 0.9632 0.0027 0.1438 0.1438 1
( 0, 4) 25 0.9768 0.0021 0.1438 0.1438 1
( 4, 0) 25 0.9540 0.0033 0.1438 0.1438 1
( 2, 2) 25 0.9592 0.0028 0.2875 0.2875 2
( 3, 1) 25 0.9598 0.0033 0.2875 0.2875 2
( 1, 3) 25 0.9638 0.0026 0.2875 0.2875 2
( 0, 4) 25 0.9772 0.0021 0.2875 0.2875 2
5000
( 4, 0) 25 0.9518 0.0033 0.2875 0.2875 2
( 2, 2) 25 0.9536 0.0021 0.1438 0.1438 1
( 3, 1) 25 0.9566 0.0022 0.1438 0.1438 1
( 1, 3) 25 0.9647 0.0018 0.1438 0.1438 1
( 0, 4) 25 0.9792 0.0014 0.1438 0.1438 1
( 4, 0) 25 0.9586 0.0022 0.1438 0.1438 1
( 2, 2) 25 0.9528 0.0021 0.2875 0.2875 2
( 3, 1) 25 0.9552 0.0023 0.2875 0.2875 2
( 1, 3) 25 0.9634 0.0019 0.2875 0.2875 2
( 0, 4) 25 0.9775 0.0015 0.2875 0.2875 2
10000
( 4, 0) 25 0.9561 0.0023 0.2875 0.2875 2
Table 2.2: Simulation Result when itersize = 2000,5000 and 10000 and n∗ = 25
parametric configurations for the case when k = 6. Note that the configuration (3, 3) is the
Least favorable Configuration under which there are all equal number of treatments on the
two boundaries as discussed before. And, the other parametric configurations summarized in the
Table 2.8 are (0, 6), (2, 4), (1, 5), (5, 5), (4, 2)and (6, 0).
The findings in the Table 2.8 confirm the theoretical results derived in the Theorem 1 that the
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 2, 2) 50 0.9580 0.0045 0.0719 0.0719 1
( 3, 1) 50 0.9545 0.0047 0.0719 0.0719 1
( 1, 3) 50 0.9660 0.0041 0.0719 0.0719 1
( 0, 4) 50 0.9770 0.0034 0.0719 0.0719 1
( 2, 2) 50 0.9565 0.0046 0.1438 0.1438 2
( 3, 1) 50 0.9580 0.0045 0.1438 0.1438 2
( 1, 3) 50 0.9715 0.0037 0.1438 0.1438 2
( 0, 4) 50 0.9800 0.0030 0.1438 0.1438 2
5000
( 2, 2) 50 0.9550 0.0029 0.0719 0.0719 1
( 3, 1) 50 0.9646 0.0032 0.0719 0.0719 1
( 1, 3) 50 0.9648 0.0026 0.0719 0.0719 1
( 0, 4) 50 0.9778 0.0021 0.0719 0.0719 1
( 2, 2) 50 0.9514 0.0030 0.1438 0.1438 2
( 3, 1) 50 0.9524 0.0030 0.1438 0.1438 2
( 1, 3) 50 0.9624 0.0027 0.1438 0.1438 2
( 0, 4) 50 0.9794 0.0020 0.1438 0.1438 2
10000
( 2, 2) 50 0.9537 0.0029 0.0719 0.0719 1
( 3, 1) 50 0.9547 0.0023 0.0719 0.0719 1
( 1, 3) 50 0.9649 0.0026 0.0719 0.0719 1
( 0, 4) 50 0.9777 0.0015 0.0719 0.0719 1
( 2, 2) 50 0.9558 0.0030 0.1438 0.1438 2
( 3, 1) 50 0.9562 0.0023 0.1438 0.1438 2
( 1, 3) 50 0.9664 0.0027 0.1438 0.1438 2
( 0, 4) 50 0.9781 0.0015 0.1438 0.1438 2
Table 2.3: Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 50
generalized partition procedure satisfies the probability requirement (2.10) for all the parametric
configurations. And, one will also note that the estimated value of the probability of the correct
decision is least for the parametric configuration (3,3). Which verifies that this is the parametric
configuration for which the P (CD) is least among all parametric configurations.
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 2, 2) 100 0.9490 0.0049 0.0360 0.0360 1
( 3, 1) 100 0.9490 0.0050 0.0360 0.0360 1
( 1, 3) 100 0.9625 0.0042 0.0360 0.0360 1
( 0, 4) 100 0.9730 0.0036 0.0360 0.0360 1
( 2, 2) 100 0.9610 0.0043 0.0719 0.0719 2
( 3, 1) 100 0.9510 0.0048 0.0719 0.0719 2
( 1, 3) 100 0.9645 0.0041 0.0719 0.0719 2
( 0, 4) 100 0.9810 0.0031 0.0719 0.0719 2
5000
( 2, 2) 100 0.9534 0.0030 0.0360 0.0360 1
( 3, 1) 100 0.9554 0.0032 0.0360 0.0360 1
( 1, 3) 100 0.9672 0.0025 0.0360 0.0360 1
( 0, 4) 100 0.9772 0.0021 0.0360 0.0360 1
( 2, 2) 100 0.9596 0.0028 0.0719 0.0719 2
( 3, 1) 100 0.9522 0.0034 0.0719 0.0719 2
( 1, 3) 100 0.9663 0.0026 0.0719 0.0719 2
( 0, 4) 100 0.9774 0.0021 0.0719 0.0719 2
10000
( 2, 2) 100 0.9499 0.0022 0.0360 0.0360 1
( 3, 1) 100 0.9554 0.0023 0.0360 0.0360 1
( 1, 3) 100 0.9650 0.0018 0.0360 0.0360 1
( 0, 4) 100 0.9784 0.0015 0.0360 0.0360 1
( 2, 2) 100 0.9567 0.0020 0.0719 0.0719 2
( 3, 1) 100 0.9577 0.0022 0.0719 0.0719 2
( 1, 3) 100 0.9656 0.0018 0.0719 0.0719 2
( 0, 4) 100 0.9762 0.0015 0.0719 0.0719 2
Table 2.4: Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 100
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 2, 2) 200 0.9415 0.0052 0.0178 0.0178 1
( 3, 1) 200 0.9410 0.0048 0.0178 0.0178 1
( 1, 3) 200 0.9605 0.0044 0.0178 0.0178 1
( 0, 4) 200 0.9755 0.0035 0.0178 0.0178 1
( 2, 2) 200 0.9595 0.0044 0.0360 0.0360 2
( 3, 1) 200 0.9445 0.0051 0.0360 0.0360 2
( 1, 3) 200 0.9685 0.0039 0.0360 0.0360 2
( 0, 4) 200 0.9810 0.0031 0.0360 0.0360 2
5000
( 2, 2) 200 0.9514 0.0030 0.0178 0.0178 1
( 3, 1) 200 0.9530 0.0033 0.0178 0.0178 1
( 1, 3) 200 0.9664 0.0025 0.0178 0.0178 1
( 0, 4) 200 0.9740 0.0023 0.0178 0.0178 1
( 2, 2) 200 0.9558 0.0029 0.0360 0.0360 2
( 3, 1) 200 0.9546 0.0032 0.0360 0.0360 2
( 1, 3) 200 0.9620 0.0027 0.0360 0.0360 2
( 0, 4) 200 0.9812 0.0019 0.0360 0.0360 2
10000
( 2, 2) 200 0.9533 0.0021 0.0178 0.0178 1
( 3, 1) 200 0.9545 0.0023 0.0178 0.0178 1
( 1, 3) 200 0.9652 0.0018 0.0178 0.0178 1
( 0, 4) 200 0.9784 0.0015 0.0178 0.0178 1
( 2, 2) 200 0.9571 0.0020 0.0360 0.0360 2
( 3, 1) 200 0.9583 0.0022 0.0360 0.0360 2
( 1, 3) 200 0.9648 0.0018 0.0360 0.0360 2
( 0, 4) 200 0.9746 0.0016 0.0360 0.0360 2
Table 2.5: Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 200
configuration n∗ p std(p) δ∗ a σ
( 2, 2) 400 0.9496 0.0031 0.0090 0.0090 1
( 3, 1) 400 0.9434 0.0033 0.0090 0.0090 1
( 1, 3) 400 0.9638 0.0026 0.0090 0.0090 1
( 0, 4) 400 0.9754 0.0022 0.0090 0.0090 1
( 2, 2) 400 0.9516 0.003 0.0180 0.0180 2
( 3, 1) 400 0.947 0.0032 0.0180 0.0180 2
( 1, 3) 400 0.9692 0.0024 0.0180 0.0180 2
( 0, 4) 400 0.9712 0.0024 0.0180 0.0180 2
Table 2.6: Simulation Result when itersize =5000 and n∗ = 400
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configuration n∗ p std(p) δ∗ a σ
( 2, 2) 800 0.9546 0.0029 0.0045 0.0045 1
( 3, 1) 800 0.9478 0.0031 0.0045 0.0045 1
( 1, 3) 800 0.9654 0.0026 0.0045 0.0045 1
( 0, 4) 800 0.9786 0.002 0.0045 0.0045 1
( 2, 2) 800 0.951 0.0031 0.0090 0.0090 2
( 3, 1) 800 0.9496 0.0031 0.0090 0.0090 2
( 1, 3) 800 0.9628 0.0027 0.0090 0.0090 2
( 0, 4) 800 0.9794 0.002 0.0090 0.0090 2
Table 2.7: Simulation Result when itersize =5000 and n∗ = 800
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 0, 6) 25 0.9700 0.0032 0.1579 0.1579 1
( 1, 5) 25 0.9760 0.0032 0.1579 0.1579 1
( 2, 4) 25 0.9650 0.0041 0.1579 0.1579 1
( 3, 3) 25 0.9565 0.0046 0.1579 0.1579 1
( 4, 2) 25 0.9575 0.0048 0.1579 0.1579 1
( 5, 1) 25 0.9570 0.0053 0.1579 0.1579 1
( 0, 6) 25 0.9850 0.0027 0.3159 0.3159 2
( 1, 5) 25 0.9785 0.0032 0.3159 0.3159 2
( 2, 4) 25 0.9720 0.0037 0.3159 0.3159 2
( 3, 3) 25 0.9630 0.0042 0.3159 0.3159 2
( 4, 2) 25 0.9580 0.0050 0.3159 0.3159 2
( 5, 1) 25 0.9600 0.0053 0.3159 0.3159 2
5000
( 0, 6) 25 0.9822 0.0019 0.1579 0.1579 1
( 1, 5) 25 0.9750 0.0022 0.1579 0.1579 1
( 2, 4) 25 0.9646 0.0026 0.1579 0.1579 1
( 3, 3) 25 0.9542 0.0030 0.1579 0.1579 1
( 4, 2) 25 0.9552 0.0031 0.1579 0.1579 1
( 5, 1) 25 0.9530 0.0033 0.1579 0.1579 1
( 0, 6) 25 0.9810 0.0019 0.1579 0.1579 2
( 1, 5) 25 0.9782 0.0021 0.3159 0.3159 2
( 2, 4) 25 0.9640 0.0037 0.3159 0.3159 2
( 3, 3) 25 0.9540 0.0029 0.3159 0.3159 2
( 4, 2) 25 0.9576 0.0032 0.3159 0.3159 2
( 5, 1) 25 0.9544 0.0032 0.3159 0.3159 2
10000
( 0, 6) 25 0.9798 0.0014 0.1579 0.1579 1
( 1, 5) 25 0.9730 0.0016 0.1579 0.1579 1
( 2, 4) 25 0.9647 0.0018 0.1579 0.1579 1
( 3, 3) 25 0.9553 0.0020 0.1579 0.1579 1
( 4, 2) 25 0.9581 0.0022 0.1579 0.1579 1
( 5, 1) 25 0.9561 0.0023 0.1579 0.1579 1
( 0, 6) 25 0.9845 0.0012 0.3159 0.3159 2
( 1, 5) 25 0.9742 0.0016 0.3159 0.3159 2
( 2, 4) 25 0.9667 0.0018 0.3159 0.3159 2
( 3, 3) 25 0.9530 0.0021 0.3159 0.3159 2
( 4, 2) 25 0.9590 0.0021 0.3159 0.3159 2
( 5, 1) 25 0.9546 0.0023 0.3159 0.3159 2
Table 2.8: Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 25
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 0, 6) 50 0.9800 0.0031 0.0790 0.0790 1
( 1, 5) 50 0.9710 0.0038 0.0790 0.0790 1
( 2, 4) 50 0.9655 0.0041 0.0790 0.0790 1
( 3, 3) 50 0.9605 0.0049 0.0790 0.0790 1
( 4, 2) 50 0.9655 0.0046 0.0790 0.0790 1
( 5, 1) 50 0.9560 0.0051 0.0790 0.0790 1
( 0, 6) 50 0.9870 0.0025 0.1580 0.1580 2
( 1, 5) 50 0.9735 0.0036 0.1580 0.1580 2
( 2, 4) 50 0.9650 0.0041 0.1580 0.1580 2
( 3, 3) 50 0.9550 0.0046 0.1580 0.1580 2
( 4, 2) 50 0.9565 0.0046 0.1580 0.1580 2
( 5, 1) 50 0.9594 0.0049 0.1580 0.1580 2
5000
( 0, 6) 50 0.9842 0.0018 0.0790 0.0790 1
( 1, 5) 50 0.9742 0.0022 0.0790 0.0790 1
( 2, 4) 50 0.9686 0.0025 0.0790 0.0790 1
( 3, 3) 50 0.9484 0.0028 0.0790 0.0790 1
( 4, 2) 50 0.9486 0.0031 0.0790 0.0790 1
( 5, 1) 50 0.9516 0.0033 0.0790 0.0790 1
( 0, 6) 50 0.9824 0.0019 0.1580 0.1580 2
( 1, 5) 50 0.9782 0.0021 0.1580 0.1580 2
( 2, 4) 50 0.9688 0.0025 0.1580 0.1580 2
( 3, 3) 50 0.9566 0.0029 0.1580 0.1580 2
( 4, 2) 50 0.9586 0.0031 0.1580 0.1580 2
( 5, 1) 50 0.9644 0.0032 0.1580 0.1580 2
10000
( 0, 6) 50 0.9846 0.0012 0.0790 0.0790 1
( 1, 5) 50 0.9775 0.0015 0.0790 0.0790 1
( 2, 4) 50 0.9625 0.0019 0.0790 0.0790 1
( 3, 3) 50 0.9530 0.0020 0.0790 0.0790 1
( 4, 2) 50 0.9586 0.0022 0.0790 0.0790 1
( 5, 1) 50 0.9558 0.0023 0.0790 0.0790 1
( 0, 6) 50 0.9827 0.0013 0.1580 0.1580 2
( 1, 5) 50 0.9758 0.0015 0.1580 0.1580 2
( 2, 4) 50 0.9666 0.0018 0.1580 0.1580 2
( 3, 3) 50 0.9549 0.0021 0.1580 0.1580 2
( 4, 2) 50 0.9570 0.0022 0.1580 0.1580 2
( 5, 1) 50 0.9555 0.0023 0.1580 0.1580 2
Table 2.9: Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 50
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itersize configuration n∗ p std(p) δ∗ a σ
2000
( 0, 6) 100 0.9850 0.0027 0.0395 0.0395 1
( 1, 5) 100 0.9765 0.0034 0.0395 0.0395 1
( 2, 4) 100 0.9675 0.0041 0.0395 0.0395 1
( 3, 3) 100 0.9560 0.0046 0.0395 0.0395 1
( 4, 2) 100 0.9595 0.0053 0.0395 0.0395 1
( 5, 1) 100 0.9552 0.0052 0.0395 0.0395 1
( 0, 6) 100 0.9845 0.0028 0.0790 0.0790 2
( 1, 5) 100 0.9695 0.0038 0.0790 0.0790 2
( 2, 4) 100 0.9675 0.0041 0.0790 0.0790 2
( 3, 3) 100 0.9580 0.0045 0.0790 0.0790 2
( 4, 2) 100 0.9570 0.0050 0.0790 0.0790 2
( 5, 1) 100 0.9530 0.0047 0.0790 0.0790 2
5000
( 0, 6) 100 0.9824 0.0019 0.0395 0.0395 1
( 1, 5) 100 0.9746 0.0022 0.0395 0.0395 1
( 2, 4) 100 0.9644 0.0026 0.0395 0.0395 1
( 3, 3) 100 0.9526 0.0028 0.0395 0.0395 1
( 4, 2) 100 0.9544 0.0030 0.0395 0.0395 1
( 5, 1) 100 0.9566 0.0032 0.0395 0.0395 1
( 0, 6) 100 0.9834 0.0018 0.0790 0.0790 2
( 1, 5) 100 0.9735 0.0036 0.0790 0.0790 2
( 2, 4) 100 0.9650 0.0041 0.0790 0.0790 2
( 3, 3) 100 0.9550 0.0046 0.0790 0.0790 2
( 4, 2) 100 0.9565 0.0046 0.0790 0.0790 2
( 5, 1) 100 0.9594 0.0049 0.0790 0.0790 2
10000
( 0, 6) 100 0.9862 0.0012 0.0395 0.0395 1
( 1, 5) 100 0.9756 0.0015 0.0395 0.0395 1
( 2, 4) 100 0.9643 0.0019 0.0395 0.0395 1
( 3, 3) 100 0.9552 0.0021 0.0395 0.0395 1
( 4, 2) 100 0.9595 0.0022 0.0395 0.0395 1
( 5, 1) 100 0.9558 0.0024 0.0395 0.0395 1
( 0, 6) 100 0.9818 0.0013 0.0790 0.0790 2
( 1, 5) 100 0.9733 0.0016 0.0790 0.0790 2
( 2, 4) 100 0.9671 0.0018 0.0790 0.0790 2
( 3, 3) 100 0.9501 0.0020 0.0790 0.0790 2
( 4, 2) 100 0.9552 0.0021 0.0790 0.0790 2
( 5, 1) 100 0.9507 0.0024 0.0790 0.0790 2
Table 2.10: Simulation Result when itersize = 2000, 5000 and 10000 and n∗ = 100
45
configuration n∗ p std(p) δ∗ a σ
( 0, 6) 400 0.9829 0.0013 0.0099 0.0099 1
( 1, 5) 400 0.9767 0.0015 0.0099 0.0099 1
( 2, 4) 400 0.9673 0.0018 0.0099 0.0099 1
( 3, 3) 400 0.9555 0.0021 0.0099 0.0099 1
( 4, 2) 400 0.9565 0.0023 0.0099 0.0099 1
( 5, 1) 400 0.9585 0.0023 0.0099 0.0099 1
( 0, 6) 400 0.9829 0.0013 0.0197 0.0197 2
( 1, 5) 400 0.9757 0.0015 0.0197 0.0197 2
( 2, 4) 400 0.9648 0.0018 0.0197 0.0197 2
( 3, 3) 400 0.9537 0.0021 0.0197 0.0197 2
( 4, 2) 400 0.9564 0.0023 0.0197 0.0197 2
( 5, 1) 400 0.9562 0.0023 0.0197 0.0197 2
Table 2.11: Simulation Result when itersize =10000 and n∗ = 400
configuration n∗ p std(p) δ∗ a σ
( 0, 6) 800 0.9832 0.0013 0.0049 0.0049 1
( 1, 5) 800 0.9762 0.0015 0.0049 0.0049 1
( 2, 4) 800 0.9660 0.0018 0.0049 0.0049 1
( 3, 3) 800 0.9538 0.0020 0.0049 0.0049 1
( 4, 2) 800 0.9593 0.0022 0.0049 0.0049 1
( 5, 1) 800 0.9583 0.0022 0.0049 0.0049 1
( 0, 6) 800 0.9827 0.0013 0.0099 0.0099 2
( 1, 5) 800 0.9746 0.0016 0.0099 0.0099 2
( 2, 4) 800 0.9653 0.0018 0.0099 0.0099 2
( 3, 3) 800 0.9565 0.0020 0.0099 0.0099 2
( 4, 2) 800 0.9568 0.0023 0.0099 0.0099 2
( 5, 1) 800 0.9591 0.0023 0.0099 0.0099 2
Table 2.12: Simulation Result when itersize =10000 and n∗ = 800
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Chapter 3
A Purely Sequential Procedure for Partition a Set of Exponential
Populations
3.1 Purely sequential procedure
In this Chapter we will propose a purely sequential procedure for the partition problem introduced
in the chapter 2 for the unknown σ2 case. The purely sequential procedure starts with observations
X0j, X1j, · · · , Xkj , j = 1, · · · ,m, where m (≥2) is the starting sample size from pi0, pi1, · · · , pik.
After this, the sampling continues with one observation from pi0, pi1, · · · , pik, at each step, accord-
ing to the stopping rule
N = inf{n ≥ m : n ≥ bσˆ
a
}, (3.1)
where σˆ is an estimator of σ based on a sample of size n along the lines of (2.6). A purely sequential
procedure is the one where one keeps taking one sample at a time from each population, after the
start, till some boundary condition is met involving the sample size and the corresponding estimate
of the optimal sample sizes n∗.
The purely sequential procedures of Robbin (1959), Chow and Robbin (1965), Starr and
Woodroofe (1972), Mukhopadhyay (1974) and many others have the same form given in (3.1).
Under certain special circumstances, Siegmund (1968) and Bhattacharyya and Mallik (1973) s-
tudied asymptotic distribution of properly standardized stopping variables arising from specific
sequential processes. We now mention a few analogous results under the general framework (3.1)
along the lines of Ghosh and Mukhopadhyay’s (1975) development.
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Theorem 2 For the purely sequential procedure (3.1) and using the decision rule (2.7) based on
a sample of size N from pi0, pi1, · · · , pik, we have as a→ 0:
(i) N/n∗c → 1 w.p. 1;
(ii) E(N/n∗c)→ 1;
(iii) lim inf P (CD)] ≥ P ∗ for all µ ∈ Rk+1;
where n∗c =
bσ
a
and b comes from (2.13), and a comes from (2.4).
Proof: Utilizing Lemma 1 of Chow and Robbins (1965), it follows that as a→ 0, we have
N→ ∞, σˆ → σ w.p. 1. The basic inequality is then equivalent to
bσˆa−1 ≤ N ≤ m+ bσˆa−1, (3.2)
Now divide throughout (3.2) by n∗c , one gets
σˆ/σ ≤ N/n∗c ≤ ma/bσ + σˆ/σ,
and then take limits as a→ 0. This leads to part(i). Then by employing Helmert’s orthogonal
transformation, σˆ can be write as the sample mean of i.i.d random variables such as
σˆ = (n− 1)−1Σn−1i=1W ′i , (3.3)
where W ′1,W
′
2, . . ., are i.i.d.
1
2
(k + 1)−1σχ22(k+1) random variables. In fact, from Lombard and
Swanepoel (1978) it does follow that N given by (3.1) has exactly the same distribution as that of
N = inf{n ≥ m : n ≥ ba−1(n− 1)−1Σn−1i=1W ′i}. (3.4)
LetW ∗ = sup
n≥2
{(n−1)−1Σn−1i=1W ′i}, from the right hand side of the basic inequality (3.2), it follows
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that
N ≤ m+ ba−1W ∗
that is N/n∗c ≤ m + σ−1W ∗ for sufficiently small a. By Wiener’s (1939) dominated ergodic the-
orem one can conclude that E(W ∗) < ∞. Now, the dominated convergence theorem and part (i)
together can easily be seen to imply part (ii).
Next, to prove the part (iii),
P
[
CD|θ0(r′), σ, ℘
]
≥ P
[
Tj − T0 < d, Ti − T0 > d,
]
≥ P
[
Tj − T0 − θj + θ0 < d− θj + θ0, Ti − T0 − θi + θ0 > d− θi + θ0,
]
≥ P
[
(Tj−T0−θj+θ0)
σ/n
<
d−θj+θ0
σ/n
, Ti−T0−θi+θ0
σ/n
> d−θi+θ0
σ/n
,
]
≥ P
[
Tj−θj
σ/n
− T0−θ0
σ/n
<
d−θj+θ0
σ/n
, Ti−θi
σ/n
− T0−θ0
σ/n
> d−θi+θ0
σ/n
,
]
≥ P
[
Yj − Y0 <
δ1+δ2
2
−θj+θ0
σ/n
, Y0 − Yi <
δ1+δ2
2
−θj+θ0
σ/n
,
]
≥ P
[
Yj − Y0 <
δ1
2
+
δ2
2
−θ0−δ0+θ0
σ/n
, Y0 − Yi <
δ1+δ2
2
−θj+θ0
σ/n
,
]
≥ P
[
Yj − Y0 <
δ2−δ1
2
σ/n
, Y0 − Yi <
δ1+δ2
2
−θj+θ0
σ/n
, 0 < i ≤ r′, r′ < j ≤ k
]
≥ P
[
Yj − Y0 < anσ , Y0 − Yi < anσ , 0 < i ≤ r′, r′ < j ≤ k
]
.
can be further write as
P
[
CD
]
≥ P
[
Yi − Y0 < aN
σ
, i = 1, · · · , k
]
= P
[
Yi <
aN
σ
+ Y0, i = 1, · · · , k
]
= E
[ ∞∫
0
{1− exp(−y − aN
σ
)}k−1exp(−y)dy|Y0 = y
]
. (3.5)
Also, from part (i), one get aN/σ → bw.p.1 as a→ 0, and hence (3.4) together with the dominated
convergence theorem will lead to part (iii). This complete the proof of Theorem 2. 
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3.2 Nonlinear Renewal Theory of The Purely Sequential Procedure
The nonlinear renewal theory was developed and fully exploited in the area of sequential analysis
in order to derive asymptotic second-order expansions of the risk functions associated with cer-
tain specific problems in the area of estimation and testing of hypotheses. Major breakthroughs
came from Lai and Siegmund (1997, 1979) and Woodroofe (1977). See also the comprehensive
accounts in Woodroofe (1982, 1991) and Segmund (1985). In what follows, we consider the setup
discussed in Woodroofe (1977); however, we also present some of the materials along the lines of
Mukhopadhyay and Solanky (1994).
Theorem 3 For the purely sequential procedure (3.1), we have as a→ 0:
(i) E(N) = C + β
′′
+ o(1) for all µ ∈ Rk+1 if m ≥ 2 when k ≥ 2;
(ii) P (CS) = P ∗ − aσ−1{β ′′b1 − 12bb2(k + 1)−1}+ o(δ∗) under the LFC for m ≥ 2 when k ≥ 2 ;
where β
′′
= (k + 1)−1(1
2
ν − 1) with ν defined in (3.7).
Proof: For the purely sequential procedure (3.1) we will derive a second-order expansions.
Use the representation given in (3.4) to rewrite
N = inf{n ≥ m : 2(k + 1)n(n− 1)n∗−1c ≥ Σn−1i=1Wi}
with Wi = 2(k + 1)σ−1W ′i . And hence N = Q +1 where
Q = inf{n ≥ m− 1 : 2(k + 1)n(n+ 1)n∗−1c ≥ Σn−1i=1Wi}, (3.6)
W ′is being i.i.d. χ
2
2(k+1). Now, Q agrees with δ = 2, L0 = 1, h
∗ = 2(k + 1)/n∗c , θ = E(W1) =
2(k + 1), τ 2 = E(W 21 )− θ2 = 4(k + 1), β∗ = 1δ−1 = 1, n∗0 = n∗c , p = 1k+1 , b = k + 1,and
ν = (k + 2)− Σ∞n=1n−1E[max(0, χ22n(k+1) − 4n(k + 1))]. (3.7)
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The second-order theory summarized here was originally developed in Mukhopadhyay (1986) for
general k ≥ 2. The case when k = 2 was considered in Mukhopadhyay (1984). Let
q1(x) = exp(−1)I(x > 0), b(k, x) =
(
k − 1
x
)
(−1)x(x+ 1)−1, (3.8)
bi = Σ
k−1
x=0x
ib(k, x)q1(xa), for i = 1, 2, and (3.9)
g1(y) =
∫ ∞
0
{1− exp(−z − y)}k−1exp(−z)dz for y > 0. (3.10)
Let us first prove part (i). Note that η corresponding to Q given in (3.6) simplifies to (k +
1)−1(1
2
ν − 1) − 1 and hence the theorem 2.4.8(v) of Mukhopadhyay and Solanky (1994) with
ω = 1 leads to
E(N) = 1 + E(Q) = 1 + n∗c + η + o(1) = n
∗
c + (k + 1)
−1(
1
2
ν − 1) + o(1) (3.11)
if m − 1 > 2(k + 1)−1, that is, if m > 2(k + 1)−1 + 1. This is part (i). Let us turn now to prove
part (ii). We have under the LFC,
P (CS) = P
[
Yj − Y0 < an
σ
, Y0 − Yi < an
σ
, 0 < i ≤ r′, r′ < j ≤ k
]
= E
[ ∫ ∞
0
{1− exp(−y − aN/σ)}k−1exp(−y)dy
]
= E
[
g1(aN/σ)
]
= Σk−1j=0b(k, j)E
[
q1(jaN/σ)
]
= Σk−1j=0b(k, j)E
[
e−jb − e−jb(jaN/σ − jb) + 1
2
e−W
∗
j (jaN/σ − jb)2]
= Σk−1j=0b(k, j)q1(jb)− Σk−1j=0b(k, j)jaσ−1E
[
N − bσ/a]q1(jb)
+
1
2
Σk−1j=0b(k, j)j
2abσ−1E
[
U∗2q1(W ∗j )
]
(3.12)
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for a suitable random variable W ∗j between jb and jaN/b. Since U
∗ = (N − n∗c)n∗−
1
2
c . Again,
U∗2q1(W ∗j ) is uniformly integrable if m > 1 + (k+ 1)
−1. Also, U∗2q1(W ∗j )
ξ→ (k+ 1)−1q1(jb)χ21
as a→ 0. Now, from (3.12), one obtains for m > 1 + 2(k + 1)−1, that is, for m ≥ 2,
P (CS) = P ∗ − aσ−1b1E
[
N − n∗c
]
+
1
2
ba(k + 1)−1σ−1(b2 + o(2))
= P ∗ − aσ−1b1(β ′′ + o(1)) + 1
2
ba(k + 1)−1σ−1(b2 + o(2))
= P ∗ − aσ−1{β ′′b1 − 1
2
bb2(k + 1)
−1}+ o(σ∗), (3.13)
in view of (3.8) - (3.10) and (3.11). This is part (iii).
3.3 Monte-Carlo Simulation
Next, the purely sequential procedure (3.1) is simulated. The procedure (3.1) starts with m(≥ 2)
observations from each of the k treatments and the control population. The procedure takes one
additional sample at a time from each all the k treatments and the control population according
to the following stopping rule (3.1).For the simulations reported in this section, we considered the
value of k = 4, and P ∗ = 0.95. The value of the design constant b was obtained from Table 2.1
for the given value of k and P ∗. As before, the design parameters δ1 and δ2 are provided by the
experimenter based on the definition of the “Good” and “Bad” populations.
Recall that theoretically from the Theorem 3, the purely sequential procedure (3.1) over-
samples by a third of a sample asymptotically. The simulated values in Table (3.1 - 3.3) confirm
this asymptotic difference between the n¯ and n∗ in every instance. Also, note that the average value
of the probability of correct decision P¯ matches the target value of 0.95 in all the cases considered.
The findings in Table (3.1 - 3.3) also confirm the theoretical results derived in Theorem 2 and 3 for
the purely sequential procedure.
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(k1, k2) n∗ n std(n) p std(p) a b
( 2, 2)
25 25.387 0.051 0.9535 0.0044 0.1438 3.5938
50 50.3705 0.0702 0.9525 0.0048 0.0719 3.5938
100 100.307 0.1018 0.956 0.0044 0.0359 3.5938
200 200.5775 0.1485 0.953 0.0044 0.0180 3.5938
400 400.36 0.1986 0.9556 0.0044 0.0090 3.5938
800 800.49 0.2746 0.9563 0.0044 0.0045 3.5938
( 1, 3)
25 25.423 0.0526 0.9585 0.0039 0.1438 3.5938
50 50.3955 0.0739 0.9675 0.0036 0.0719 3.5938
100 100.623 0.1032 0.9665 0.0043 0.0359 3.5938
200 200.463 0.1233 0.9587 0.0044 0.0180 3.5938
400 400.33 0.276 0.9762 0.0037 0.0090 3.5938
800 800.421 0.2700 0.9665 0.004 0.0045 3.5938
( 3, 1)
25 25.3055 0.0521 0.9630 0.0052 0.1438 3.5938
50 50.223 0.0721 0.9621 0.0050 0.0719 3.5938
100 100.421 0.1224 0.9595 0.0051 0.0359 3.5938
200 200.166 0.1431 0.9578 0.0050 0.0180 3.5938
400 400.231 0.1642 0.9691 0.0051 0.0090 3.5938
800 800.677 0.2670 0.9712 0.0051 0.0045 3.5938
Table 3.1: Simulation Result when itersize = 2000 and σ = 1
(k1, k2) n∗ n std(n) p std(p) a b
( 2, 2)
25 25.3616 0.0325 0.9586 0.0028 0.1438 3.5938
50 50.386 0.0454 0.9544 0.003 0.0719 3.5938
100 100.322 0.1102 0.9571 0.0041 0.0359 3.5938
200 200.298 0.1256 0.9562 0.0040 0.0180 3.5938
400 400.3131 0.166 0.9559 0.0043 0.0090 3.5938
800 800.257 0.2272 0.9565 0.0041 0.0045 3.5938
( 1, 3)
25 25.3554 0.0334 0.9626 0.0027 0.1438 3.5938
50 50.322 0.0622 0.9675 0.0033 0.0719 3.5938
100 100.281 0.1217 0.9671 0.0033 0.0359 3.5938
200 200.221 0.1301 0.9591 0.0044 0.0180 3.5938
400 400.199 0.2224 0.9612 0.0037 0.0090 3.5938
800 800.381 0.2622 0.9575 0.0040 0.0045 3.5938
( 3, 1)
25 25.442 0.0328 0.9594 0.0031 0.1438 3.5938
50 50.373 0.0662 0.9601 0.0031 0.0719 3.5938
100 100.411 0.1621 0.9645 0.0051 0.0359 3.5938
200 200.301 0.1890 0.9578 0.0044 0.0180 3.5938
400 400.229 0.1923 0.9559 0.0044 0.0090 3.5938
800 800.521 0.2601 0.9612 0.0041 0.0045 3.5938
Table 3.2: Simulation Result when itersize = 5000 and σ = 1
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(k1, k2) n∗ n std(n) p std(p) a b
( 2, 2)
25 25.382 0.0329 0.9515 0.0029 0.1438 3.5938
50 50.3 0.0708 0.951 0.0046 0.0719 3.5938
100 100.443 0.1027 0.952 0.0051 0.0359 3.5938
200 200.411 0.149 0.953 0.0047 0.0180 3.5938
400 400.497 0.196 0.954 0.0047 0.0090 3.5938
800 800.605 0.2786 0.954 0.0046 0.0045 3.5938
( 1, 3)
25 25.434 0.0532 0.968 0.0039 0.1438 3.5938
50 50.299 0.0706 0.9735 0.0036 0.0719 3.5938
100 100.281 0.1022 0.963 0.0043 0.0359 3.5938
200 200.301 0.144 0.9595 0.0044 0.0180 3.5938
400 400.563 0.267 0.972 0.0037 0.0090 3.5938
800 800.421 0.278 0.9675 0.004 0.0045 3.5938
( 3, 1)
25 25.4 0.0525 0.9565 0.005 0.1438 3.5938
50 50.273 0.0742 0.952 0.0051 0.0719 3.5938
100 100.323 0.1044 0.9545 0.0051 0.0359 3.5938
200 200.411 0.149 0.9535 0.0047 0.0180 3.5938
400 400.181 0.1946 0.9565 0.0045 0.0090 3.5938
800 800.787 0.2805 0.957 0.0045 0.0045 3.5938
Table 3.3: Simulation Result when itersize = 10000 and σ = 1
(k1, k2) n∗ n std(n) p std(p) a b
( 2, 2)
25 25.387 0.051 0.9595 0.0044 0.2875 3.5938
50 50.3705 0.0702 0.9625 0.0048 0.1438 3.5938
100 100.3435 0.1002 0.953 0.0047 0.0719 3.5938
200 200.411 0.149 0.9535 0.0047 0.0359 3.5938
400 400.278 0.1892 0.9550 0.0044 0.0180 3.5938
800 800.301 0.266 0.9533 0.0044 0.0090 3.5938
( 1, 3)
25 25.3975 0.0526 0.9685 0.0039 0.2875 3.5938
50 50.381 0.0725 0.9675 0.0040 0.1438 3.5938
100 100.426 0.1232 0.9605 0.0043 0.0719 3.5938
200 200.463 0.1031 0.9593 0.0044 0.0359 3.5938
400 400.33 0.246 0.9726 0.0040 0.0180 3.5938
800 800.472 0.2700 0.9665 0.004 0.0090 3.5938
( 3, 1)
25 25.3945 0.0521 0.9645 0.0051 0.2875 3.5938
50 50.4205 0.0708 0.9645 0.0051 0.1438 3.5938
100 100.3321 0.1124 0.9595 0.0051 0.0719 3.5938
200 200.2615 0.1430 0.9688 0.0052 0.0359 3.5938
400 400.231 0.1722 0.9691 0.0051 0.0180 3.5938
800 800.6867 0.2670 0.9672 0.0051 0.0090 3.5938
Table 3.4: Simulation Result when itersize = 2000 and σ = 2
54
(k1, k2) n∗ n std(n) p std(p) a b
( 2, 2)
25 25.387 0.051 0.9595 0.0044 0.2875 3.5938
50 50.3705 0.0702 0.9625 0.0048 0.1438 3.5938
100 100.3435 0.1002 0.953 0.0047 0.0719 3.5938
200 200.411 0.149 0.9535 0.0047 0.0359 3.5938
400 400.278 0.1892 0.9550 0.0044 0.0180 3.5938
800 800.301 0.266 0.9533 0.0044 0.0090 3.5938
( 1, 3)
25 25.3975 0.0526 0.9685 0.0039 0.2875 3.5938
50 50.381 0.0725 0.9675 0.0040 0.1438 3.5938
100 100.426 0.1232 0.9605 0.0043 0.0719 3.5938
200 200.463 0.1031 0.9593 0.0044 0.0359 3.5938
400 400.33 0.246 0.9726 0.0040 0.0180 3.5938
800 800.472 0.2700 0.9665 0.004 0.0090 3.5938
( 3, 1)
25 25.3945 0.0521 0.9645 0.0051 0.2875 3.5938
50 50.4205 0.0708 0.9645 0.0051 0.1438 3.5938
100 100.3321 0.1124 0.9595 0.0051 0.0719 3.5938
200 200.2615 0.1430 0.9688 0.0052 0.0359 3.5938
400 400.231 0.1722 0.9691 0.0051 0.0180 3.5938
800 800.6867 0.2670 0.9672 0.0051 0.0090 3.5938
Table 3.5: Simulation Result when itersize = 5000 and σ = 2
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Chapter 4
Statistical Surveillance of Cancers in Louisiana
4.1 Introduction
Cancer, known medically as a malignant neoplasm, is a broad group of various diseases, all in-
volving unregulated cell growth (Wiki). The pathogenesis of cancer can be traceable back to DNA
mutations that impact cell growth and metastasis. Substances that cause DNA mutations are known
as mutagens, and mutagens that cause cancers are known as carcinogens(wiki).
It is very complex to determine the causes of cancer. Only a small percentage of cases can be
explained by a few conditions such as specific chromosomal/genetic abnormalities (e.g., Down-
s syndrome) and ionizing radiation exposure (NCI, 2008). However, according to some studies,
cancers are primarily an environmental disease, with 90-95 % of cases attributed to environmen-
tal factors and 5-10 %due to genetics. Common environmental factors that contribute to cancer
death include tobacco, diet and obesity, infections, radiation, stress, lack of physical activity, and
environmental pollutants (Wiki).
A lot of literatures have been published for cancers and investigate the relationship between
chemical exposure and cancer incidence rate. In Wu, et al (2005) the authors examine age-specific
cancer incidence pattern among adolescents and young adults (age 15-49). The authors concluded
that epithelial cancer became the predominant type of tumor after age 40 years among male while
it was the predominant type after age 25 years among females.
In Harris and Lane (2006), the authors did a spatial and temporal study of environmental pol-
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lution, human malignancy, and public policy in Louisiana, from 1988 to 2002. Their research has
found Benzene exposure and the incidence of Acute Myelogenous Leukemia (AML). The authors
have concluded that the mean number if benzene reporting facilities best explain human malignan-
cy rates (AML) in Louisiana. When exposed to benzene, humans develop AML.
In Steinmaus, et al (2008) the authors performed a meta-analysis of cohort and case-control
studies of benzene exposure and NHL and a meta-analysis of NHL and refinery work, a potential
source of benzene exposure. The authors get the conclusion that the finding of elevated relative
risk in studies of both benzene exposure and refinery work provides further evidence that benzene
exposure causes NHL. In Mckean-Cowdin, et al (2009) the authors investigate the association be-
tween particulate components of air pollution and brain cancer risk. And the authors conclude
that the finding does not provide evidence of increased risk of brain cancer mortality due to air
pollutants. In Simonsen, et al. (2010) the authors investigate potential links between exposure to
petrochemical plant emissions and lung cancer, a population-based case-control study (LMRICS)
was conducted in eleven Louisiana parishes bordering the Mississippi River. The authors conclude
that residential proximity to petrochemical plants along the lower Mississippi thus showed no sig-
nificant association with lung cancer. In Ward, et al (1996) the authors reviewed the epidemiologic
evidence on the relationship between selected industries and cancer. The authors conclude that
employment in the rubber industry has been associated with bladder cancer, leukemia, stomach,
and lung cancer.; Workers exposed to polychlorinated biphenyls (PCBs) have reported excess mor-
tality from gastrointestinal neoplasms, hematologic neoplasms, and skin cancer; Employment in
the boot and shoe industry has been associated with nasal adenocarcinomas in England and Italy;
Hairdressers and barbers have been found to have excess bladder cancer and less consistent evi-
dence for several other sites; Workers exposed to wood dust have excess mortality from cancer of
the nasal sinuses and paranasal cavities; workers employed in the petroleum industry have limited
evidence for excess leukemia and other lymphatic and hematopoietic neoplasms, and skin cancer.
In Kaldor, et al (1984) the authors investigate the relationship between exposure to air emis-
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sions produced by the petroleum and chemical industries, and average annual cancer incidence and
major cause mortality rates among whites in Contra Costa County, California. And the authors
found, in both males and females, residential exposure to petroleum and chemical air emissions
was associated with an increased incidence of cancer of the buccal cavity and pharynx. And also
found a strong positive association between degree of residential Exposure and death rates from
cardiovascular disease and cancer, and a less strong positive association between exposure and
death rates from cerebro-vascular disease.
The goal of this thesis is to statistically study the occurrence of childhood Leukemia, child-
hood Lymphoma, childhood Brain cancer, male Prostate, adult Bladder, Female Breast, adult Non-
Hodgkins Lymphoma, and adult Acute Myeloid Leukemia in Louisiana and its possible correla-
tions with the exposure to certain carcinogenic chemicals.
4.2 Cancer Types
Cancer, also known as a malignant tumor or malignant neoplasm, is a group of diseases involving
abnormal cell growth with the potential to invade or spread to other parts of the body. Not all
tumors are cancerous; benign tumors do not spread to other parts of the body.Possible signs and
symptoms include: a new lump, abnormal bleeding, a prolonged cough, unexplained weight loss,
and a change in bowel movements, among others. While these symptoms may indicate cancer they
may also occur due to other issues. There are over 100 different known cancers that affect humans
(wikipedia).
Among the 12 major types of childhood cancer, Leukemia (blood cell cancers) and cancers of
the brain and central nervous system account for more than half of the new cases. About one-third
of childhood cancers are leukemia. The most common solid tumors are brain tumors, with other
solid tumors being less common (NCI 2008).
The great majority of cancers, some 9095 % of cases, are due to environmental factors. The
remaining 510 % are due to inherited genetics. Environmental, as used by cancer researchers,
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means any cause that is not inherited genetically, such as lifestyle, economic and behavioral factors,
and not merely pollution. Common environmental factors that contribute to cancer death include
tobacco (2530 % ), diet and obesity (3035 % ), infections (1520 % ), radiation (both ionizing
and non-ionizing, up to 10 % ), stress, lack of physical activity, and environmental pollutants
(www.boundless.com).
4.2.1 Childhood Leukemia Cancer
Leukemia is a cancer of the early blood-forming cells. In most cases, leukemia is a cancer that
start in the white blood cells, but some leukemia start in other blood cell types. Most often, the
leukemia invades the blood fairly quickly. From there it can go to other parts of the body such as
the lymphodes, spleen, liver, central nervous system (the brain and spinal cord), testicles, or other
organs (American Cancer Society 2014).
Leukemia, the most common cancer in children and teens, accounting for almost 1 out of 3
cancers, is a cancer of the white blood cells. Abnormal white blood cells form in the bone marrow.
They quickly travel through the bloodstream and crowd out healthy cells. This increases the body’s
chances of infection and other problems. Overall, however, childhood leukemia is a rare disease.
About 3 out 4 leukemia among children and teens are acute lymphocytic leukemia (ALL). Most of
the remaining cases are acute myelogenous leukemia (AML) (American Cancer Society 2014).
Symptoms of leukemia often prompt a visit to the doctor. This is a good thing because it
means the disease may be found earlier than it otherwise would. Early diagnosis can lead to more
successful treatment. Many signs and symptoms of childhood leukemia occur when leukemia
cells crowd out normal cells: Fatigue or pale skin, infections and fever, easy bleeding or bruising,
extreme fatigue or weakness, shortness of breath, and coughing.
To diagnose childhood leukemia, the doctor will take a thorough medical history and perform
a physical exam. Test are used to diagnose childhood leukemia as well as classify its type:
Initial tests may include:
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• Blood tests to measure the number of blood cells and see how they appear.
• Bone marrow aspiration and biopsy, usually taken from the pelvic bone, to confirm a diag-
nosis of leukemia.
• Lumbar puncture, or spinal tap, to check for spread of leukemia cells in the fluid that bathes
the brain and spinal cord.. . .
A pathologist examines cells from the blood tests under a microscope. This specialist also
checks bone marrow samples for the number of blood-forming cells and fat cells.
The exact cause of most cases of leukemia is undetermined. But environmental risk factors
have been found will increase the risk of getting diseases like leukemia. Exposure to chemicals
like benzene (a solvent used in the cleaning industry and in the making of some drugs, plastics,
and dyes) may cause AML and rarely, in children. Chemical exposure is more strongly linked to
an increased risk of AML other to ALL (American Cancer Society, 2013).
4.2.2 Childhood Lymphoma Cancer
Lymphoma cancer usually originate in the body’s lymphatic tissues. Lymphatic tissue include the
lymph nodes (also called lymph glands), thymus, spleen, tonsils, adenoids, and bone marrow, as
well as the channels that connect them. Although many types of cancer eventually spread to parts of
the lymphatic system, lymphomas are distinct because they actually originate there (KidsHealth).
About 1,700 kids younger than 20 years old are diagnosed with lymphoma each year in the
United States (KidsHealth). There are two types of lymphoma, they are known as Hodgkin’s
lymphoma and non-Hodgkin lymphoma (NHL). Together, they are the third most common type of
cancer in children. The appearance of their cancerous (malignant) cells depends which category
lymphoma cancer are be divided into.
Hodgkin lymphoma is marked by the presence of a type of cell called the Reed-Sternberg cell,
in the lymph nodes or in some other lymphatic tissue. Hodgkin’s lymphoma affects about 3 out of
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every 100,000 American, most commonly during early and late adulthood (between ages 15 and
40 and after age 55)(KidsHealth). A painless enlargement of the lymph nodes (a condition known
as swollen glands) located in the neck, above the collarbone, in the underarm area, or in the groin,
is the most common first symptom of Hodgkin’s lymphoma. If cancer involves the lymph nodes
in the center of the chest, pressure from this swelling may trigger an unexplained cough, shortness
of breath, or problems in blood flow to and from the heart (KidsHealth).
There are about 500 new cases of non-Hodgkin lymphoma diagnosed each year in kids in
the United States. It may occur during childhood at any age, but is rare before age 3. NHL is
slightly more common than Hodgkin disease in kids younger than 15 years old. In non-Hodgkin
lymphoma, there is malignant growth of specific types of lymphocytes (a kind of white blood
cell that collects in the lymph nodes). Since Malignant growth of lymphocytes is also one of the
forms of leukemia (acute lymphoblastic leukemia, or ALL), the distinguish between lymphoma
and leukemia in children becomes difficult.In general, people with lymphoma have no or only
minimal bone marrow involvement, whereas those with leukemia have extensive bone marrow
involvement .
Both Hodgkin disease and NHL tend to occur more often in people with certain severe immune
deficiencies including people with inherited immune defects, adults with human immunodeficien-
cy virus (HIV) infection, or those who have been treated with immunosuppressive drugs after
organ transplants (KidsHealth). The cause of most cases of childhood lymphoma is unknown,
but it is clear that children with compromised immune system are at a greater risk of developing
lymphomas. More studies have found potential association between exposure to pesticides dur-
ing parental, prenatal, and childhood and childhood lymohomas. The U.S. Surgeon General has
concluded that there is also suggestive evidence linking prenatal and postnatal exposure to envi-
ronmental tobacco smoke and childhood lymphomas (America’s Children and the Environment).
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4.2.3 Childhood Brain Cancer
Brain tumors, cause by abnormal growths inside the skull, are the most common solid tumors
in children. Approximately 1,500 children in the US diagnosed with a brain tumor each year.
Brain tumors, either malignant or benign, are tumors that originate in the cells of the brain. A
tumor is an abnormal growth of tissue (Children hospital of Wisconsin , CHW).A benign tumor
does not contain cancer cells and usually, once removed, does not recur. Malignant brain tumors
contain cancer cells. Malignant brain tumors are usually fast growing and invade surrounding
tissue (CHW).
Childhood brain and spinal cord tumors can cause headaches and other symptoms. However,
other conditions can also cause the same symptoms. The possible symptoms of brain tumors
includes:
• Morning headache or headache that goes away after vomiting
• Frequent nausea and vomiting
• Vision, hearing, and speech problems
• Loss of balance or trouble walking
• Unusual sleepiness
• Personality changes
• Seizures
• Increased head size in infants
Doctors use physical and neurological exams, lab tests, and imaging to diagnose brain tumors.
Most childhood brain tumors are diagnosed and removed in surgery. Over the past 20 years, there
has been some increase in the incidence of children diagnosed with all forms of invasive cancer.
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Treatment for children is sometimes different than for an adult. Long-term side effects are an
important issue. The options also depend on the type of tumor and where it is. Removal of the
tumor is often possible. If not, radiation, chemotherapy, or both may be used (NCI).
The known risk factors that cause children brain tumors include radiation therapy and certain
genetic syndromes, but these factors explain only a small portion of cases. Some studies have
reported an association between prenatal exposure to ionizing radiation and brain tumor while a
few smaller studies have not. Research also suggest that parental prenatal, and childhood exposure
to pesticides may lead to brain tumors in children (America’s Children and the Environment).
4.2.4 Breast Cancer
Breast cancer is the cancer that develops in tissue of the breast. Signs of breast cancer may include
a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple,
or a red scaly patch of skin. In those with distant spread of the disease, there may be bone pain,
swollen lymph nodes, shortness of breath, or yellow skin (wiki).
There are two types of breast cancer: ductal carcinoma, and lobular carcinoma. Ductal carci-
noma, the most common type of breast cancer, begins in the lining the milk ducts (thin tubes that
carry milk from the lobules of the breast to the nipple). While lobular carcinoma begins in the
lobules (milk glands) of the breast (NCI).
The lymph system is one way that breast cancers spread. This system has several parts. Lymph
nodes are small, bean-shaped collections of immune system cells (cells that are important in fight-
ing infections) that are connected by lymphatic vessels. Lymphatic vessels are like small veins,
except that they carry a clear fluid called lymph (instead of blood) away from the breast. Lymph
contains tissue fluid and waste products, as well as immune system cells. Breast cancer cells can
enter lymphatic vessels and begin to grow in lymph nodes (American Cancer Society).
If the cancer cells have spread to lymph nodes, there is a higher chance that the cells could
have also gotten into the bloodstream and spread (metastasized) to other sites in the body. The
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more lymph nodes with breast cancer cells, the more likely it is that the cancer may be found in
other organs as well. Because of this, finding cancer in one or more lymph nodes often affects the
treatment plan. Still, not all women with cancer cells in their lymph nodes develop metastases, and
some women can have no cancer cells in their lymph nodes and later develop metastases.
The primary risk factors for breast cancer are female sex and older age. Other potential risk
factors include: genetics, lack of childbearing or lack of breastfeeding, higher levels of certain
hormones, certain dietary patterns, and obesity. Recent studies have indicated that exposure to
light pollution is a risk factor for the development of breast cancer. And some research do find
the potential link between environment and breast cancer: non-industrialized countries have lower
breast cancer rates than industrialized countries. People move from non-industrialized countries
develop the same breast cancer rate in industrialized countries. Numerous synthetic chemicals, act
like estrogen (a hormone closely linked with the development of breast cancer) in our bodies, used
extensively in the manufacture of food packaging, medical products, appliance, cars, toys, credit
cards, and rainwear (Breast Cancer Action).
Women may reduce their risk of breast cancer by maintaining a healthy weight, drinking less al-
cohol, being physically active and breastfeeding their children. These modifications might prevent
38 % of breast cancers in the US, 42% in the UK, 28 % in Brazil and 20% in China. The benefits
with moderate exercise such as brisk walking are seen at all age groups including postmenopausal
women. Marine omega-3 polyunsaturated fatty acids appear to reduce the risk.
4.2.5 Prostate cancer
The prostate is a gland found only in males. It is located in front of the rectum and below the urinary
bladder. Prostate cancer, forms in prostate, is one of the most common cancers in American men.
In 2013, about 239,000 American men will be diagnosed with prostate cancer (NCI).
Almost all prostate cancers develop from the gland cell, and some of them can grow and spread
quickly, but most grow slowly. Prostate cancer cells can spread by breaking away from a prostate
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tumor. They can travel through blood vessels or lymph vessels to reach other parts of the body.
After spreading, cancer cells may attach to other tissues and grow to form new tumors that may
damage those tissues.
When prostate cancer spreads from its original place to another part of the body, the new tumor
has the same kind of abnormal cells and the same name as the primary (original) tumor. For
example, if prostate cancer spreads to the bones, the cancer cells in the bones are actually prostate
cancer cells. The disease is metastatic prostate cancer, not bone cancer. For that reason, it’s treated
as prostate cancer, not bone cancer.
The direct cause of prostate cancer has not been proved, but the risk factors for prostate cancer
development are: age, family history, hormones, race, dietary fat, dairy and calcium intake, mul-
tivitamin use, folate, cadmium exposure and dioxin exposure. Recently, the researchers from the
University of Illinois at Chicago found that exposure to low levels of bisphenol A during develop-
ment may make men more susceptible to prostate cancer later in life.
Men with prostate cancer have many treatment options. Treatment options include: Active
surveillance, Surgery, Radiation therapy, Hormone therapy, Chemotherapy, and Immunotherapy.
4.2.6 Bladder Cancer
Bladder cancer is a cancer that starts in the bladder. The bladder is the body part that holds and
releases urine. It is in the center of the lower belly area. In the United States, bladder cancers
usually start from the cells lining the bladder (called transitional cells) (PubMed Health). Other
types include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma
(cancer that begins in cells that make and release mucus and other fluids). The cells that form
squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result
of chronic irritation and inflammation.
Bladder cancer cells can spread by breaking away from the original tumor. They can spread
through the blood vessels to the liver, lungs, and bones. In addition, bladder cancer cells can
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spread through lymph vessels to nearby lymph nodes. After spreading, the cancer cells may attach
to other tissues and grow to form new tumors that may damage those tissues (NCI 2010).
The great majority of bladder cancers can be diagnosed at an early stage, when bladder cancer
is highly treatable. However, even early-stage bladder cancer is likely to recur.
The signs and symptoms for bladder cancer includes: blood in urine, frequent urination, painful
urination, back pain and pelvic pain (Mayoclinic).
The exact cause of bladder cancer in uncertain. However, the following things are more likely
to develop it:
• Smoking: Smoking is the most important risk factor for bladder cancer. Smokers are at least
3 times as likely to get bladder cancer as nonsmokers. Smoking causes about half of the
bladder cancers in both men and women. When smokers inhale, some of the carcinogens
(cancer-causing chemicals) in tobacco smoke are absorbed from the lungs and get into the
blood. From the blood, they are filtered by the kidneys and concentrated in the urine. These
chemicals in urine can damage the cells that line the inside of the bladder, which increases
the chance of cancer developing.
• Workplace exposures: Certain industrial chemicals have been linked with bladder cancer.
Chemicals called aromatic amines, such as benzidine and beta-naphthylamine, which are
sometimes used in the dye industry, can cause bladder cancer. Workers in other industries
that use certain organic chemicals also may be at risk for bladder cancer if exposure is not
limited by good workplace safety practices. The industries carrying highest risks include the
makers of rubber, leather, textiles, and paint products as well as printing companies. Other
workers with an increased risk of developing bladder cancer include painters, machinist-
s, printers, hairdressers (likely because of heavy exposure to hair dyes), and truck drivers
(likely because of exposure to diesel fumes).
• Age and gender: The risk of bladder cancer increases with age. About 9 out of 10 people
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with bladder cancer are older than 55. Bladder cancer is much more common in men than in
women.
• Personal history of bladder cancer: People who have had bladder cancer have an increased
risk of getting the disease again.
• Certain cancer treatments: People with cancer who have been treated with certain drugs
(such as cyclophosphamide) may be at increased risk of bladder cancer. Also, people who
have had radiation therapy to the abdomen or pelvis may be at increased risk.
• Arsenic: Arsenic is a poison that increases the risk of bladder cancer. In some areas of the
world, arsenic may be found at high levels in drinking water. However, the United States has
safety measures limiting the arsenic level in public drinking water.
• Family history of bladder cancer: People with family members who have bladder cancer
have a slightly increased risk of the disease.
Treatment options for people with bladder cancer are: surgery, chemotherapy, biological ther-
apy, and radiation therapy.
• Surgery: If your cancer has invaded the deeper layers of the bladder wall, you may consid-
er:Surgery to remove the entire bladder or Surgery to create a new way for urine to leave
your body.
• Biological therapy: Biological therapy, sometimes called immunotherapy, works by signal-
ing your body’s immune system to help fight cancer cells. Biological therapy for bladder
cancer is typically administered through your urethra and directly into the bladder (intraves-
ical therapy).
• Chemotherapy: Chemotherapy uses drugs to kill cancer cells. Chemotherapy treatment
for bladder cancer usually involves two or more chemotherapy drugs used in combination.
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Drugs can be given through a vein in your arm (intravenously), or they can be administered
directly to your bladder by passing a tube through your urethra (intravesical therapy)
• Radiation therapy: Radiation therapy is used infrequently in people with bladder cancer.
Radiation therapy uses high-energy beams aimed at your cancer to destroy the cancer cells.
Radiation therapy for bladder cancer usually comes from a machine that moves around your
body, directing the energy beams to precise points.
4.2.7 Non-Hodgkins Lymphoma Cancer
Non-Hodgkins Lymphoma is cancer of lymphoid tissue, which includes the lymph nodes, spleen,
and other organs of the immune system. White blood cells called lymphocytes are found in lymph
tissues. They help prevent infections. Most lymphomas start in a type of white blood cells called
B lymohocytes, or B cells (PubMed Health).Non-Hodgkin lymphomas can occur at any age and
are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are
many different types of non-Hodgkin lymphoma. These types can be divided into aggressive
(fast-growing) and indolent (slow-growing) types, and they can be formed from either B-cells or
T-cells. B-cell non-Hodgkin lymphomas include Burkitt lymphoma, chronic lymphocytic leukemi-
a/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma,
immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lym-
phoma. T-cell non-Hodgkin lymphomas include mycosis fungoides, anaplastic large cell lym-
phoma, and precursor T-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or
stem cell transplantation are usually B-cell non-Hodgkin lymphomas. Prognosis and treatment
depend on the stage and type of disease. Also called NHL (NCI 2008).
For most of the NHL cancers, the causes are unknown. But research shows that certain risk
factors increase the chance that a person will develop this disease.
In general, the risk factors for non-Hodgkin lymphoma include the following:
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• The risk of developing lymphoma may be increased by having a weakened immune system
(such as from an inherited condition or certain drugs used after an organ transplant).
• Certain infections:Having certain types of infections increases the risk of developing lym-
phoma. However, lymphoma is not contagious. You cannot catch lymphoma from another
person.
• Although Non-Hodgkin lymphoma can occur in young people, the chance of developing this
disease goes up with age. Most people with Non-Hodgkin lymphoma are older than 60.
Researchers are studying obesity and other possible risk factors for non-Hodgkin lymphoma. Peo-
ple who work with herbicides or certain other chemicals may be at increased risk of this disease.
The treatment options for NHL are determined based on the type and stage of your lymphoma,
your age, and your overall health.If your non-Hodgkin’s lymphoma is aggressive or causes signs
and symptoms, your doctor may recommend treatment. Options may include: chemotherapy,
radiation therapy, stem cell transplant, medications that enhance your immune system’s ability to
fight cancer, and medications that deliver radiation directly to cancer cells (mayoclinic).
4.2.8 Acute Myeloid Leukemia Cancer
Acute myeloid leukemia (AML), is a cancer of the myeloid line of blood cells, characterized by the
rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with
the production of normal blood cells (wiki). AML is the most common acute leukemia affecting
adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting
for approximately 1.2 % of cancer deaths in the United States, its incidence is expected to increase
as the population ages (wikipedia). In adults, AML is more common in men than women (PubMed
Health).
Persons with AML cancer have abnormal cells inside their bone marrow. The cells grow very
quickly, and replace healthy blood cells. The bone marrow, which helps the body fight infection-
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s, eventually stops functioning correctly. Persons with AML are more likely to have infections
and have an increased risk for bleeding as the numbers of healthy blood cells decrease (PubMed
Health).
Most signs and symptoms of AML are caused by the replacement of normal blood cells with
leukemic cells. A lack of normal white blood cell production makes the patient susceptible to
infections; while the leukemic cells themselves are derived from white blood cell precursors, they
have no infection-fighting capacity. A drop in red blood cell count (anemia) can cause fatigue,
paleness, and shortness of breath. A lack of platelets can lead to easy bruising or bleeding with
minor trauma (wiki).
The early signs of AML are often vague, and may be similar to those of influenza or other
common illnesses. Some generalized symptoms include fever, shortness of breath, easy bruising
or bleeding, petechiae, weakness or felling tired, and weight loss or loss of appetite (NCI).
Most of the time, the causes of AML are unknown. However, a number of risk factors for
developing AML have been identified, including:
• Preleukemia: ”Preleukemic” blood disorders, such as myelodysplastic syndrome or myelo-
proliferative disease, can evolve into AML; the exact risk depends on the type of MDS/MPS.
• Chemical exposure:Occupational chemical exposure to benzene and other aromatic organic
solvents is controversial as a cause of AML. Benzene and many of its derivatives are known
to be carcinogenic in vitro. While some studies have suggested a link between occupational
exposure to benzene and increased risk of AML,others have suggested the attributable risk,
if any, is slight.
• Radiation:High amounts of ionizing radiation exposure can increase the risk of AML. Sur-
vivors of the atomic bombings of Hiroshima and Nagasaki had an increased rate of AML, as
did radiologists exposed to high levels of X-rays prior to the adoption of modern radiation
safety practices.
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• Genetics: A hereditary risk for AML appears to exist. Multiple cases of AML developing
in a family at a rate higher than predicted by chance alone have been reported. Several
congenital conditions may increase the risk of leukemia; the most common is probably Down
syndrome, which is associated with a 10- to 18-fold increase in the risk of AML.
Different types of treatment are available for patients with adult acute myeloid leukemia (AML).
Some treatments are standard (the currently used treatment), and some are being tested in clinical
trials. A treatment clinical trial is a research study meant to help improve current treatments or
obtain information on new treatments for patients with cancer. When clinical trials show that a
new treatment is better than the standard treatment, the new treatment may become the standard
treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are
open only to patients who have not started treatment (NCI 2014).
The 2 treatment phases of adult AML are:
• Remission induction therapy: This is the first phase of treatment. The goal is to kill the
leukemia cells in the blood and bone marrow. This puts the leukemia into remission.
• Post-remission therapy: This is the second phase of treatment. It begins after the leukemia is
in remission. The goal of post-remission therapy is to kill any remaining leukemia cells that
may not be active but could begin to regrow and cause a relapse. This phase is also called
remission continuation therapy.
4.3 Benzene
4.3.1 What is Benzene?
Benzene is a colorless, flammable liquid with a sweet odor. It evaporates quickly when exposed
to air. Benzene is formed from natural processes, such as volcanoes and forest fires, but most
exposure to benzene results from human activities.
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Benzene is among the 20 most widely used chemicals in the United States. It is used mainly
as a starting material in making other chemicals, including plastics, lubricants, rubbers, dyes,
detergents, drugs, and pesticides. In the past it was also commonly used as an industrial solvent (a
substance that can dissolve or extract other substances) and as a gasoline additive, but these uses
have been greatly reduced in recent decades.
Benzene is also a natural part of crude oil and gasoline (and therefore motor vehicle exhaust),
as well as cigarette smoke (American Cancer Society 2013).
4.3.2 Exposure to Benzene
The main way that people exposed to benzene is through breathing. Benzene can also be absorbed
through the skin during contact with a source such as gasoline, but this is less common because liq-
uid benzene evaparates quickly (American Cancer Society). The presence of benzene in petrol and
as a widely used industrial solvent can result in significant occupational exposure and widespread
emissions to the environment. This includes rubber industry, oil refines, chemical plants, shoe
manufacturers, and gasoline-related industries (American Cancer Society). Industrial discharge,
landfill leachate and disposal of benzene containing waste are also sources of exposure (WHO).
Benzene is a potentially dangerous chemical, so expose to high levels of benzene will cause
both short term and long term health effects.
Breathing in high dose of benzene in short term will affect the nervous system, which will
lead to drowsiness, dizziness, headaches, tremors, confusion, and unconsciousness. Consuming
foods or fluids contaminated with high levels of benzene can cause vomiting, stomach irritation,
dizziness, sleepiness, convulsions, and rapid heart rate. In extreme cases, inhaling or swallowing
very high levels of benzene can be deadly. Long term expose to benzene will harm the bone
marrow, the soft, inner parts of bones where new blood cells are made. And this will caused:
anemia, a low white blood cell count, and low blood platelet count. Also some evidence indicates
that long-term exposure to benzene might harm reproductive organs (American Cancer Society).
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4.4 Data Collection
The data for the research was collected from reputation source as described below:
4.4.1 Cancer Data Collection
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Insti-
tute (NCI), an authoritative source of information on cancer incidence and survival in the United
States, works to provide information on cancer statistics in an effect to reduce the incidence of
cancer in U.S. The cancer incidence and survival data from population-based cancer registries that
been collected and published by SEER covers approximately 28 percent of the US population. The
coverage includes 26 percent of African Americans, 38 percent of Hispanics, 44 percent of Ameri-
can Indians and Alaska Natives, 50 percent of Asians, and 67 percent of Hawaiian/Pacific Islanders
(For more details, refer to Appendix). And the SEER research data, released every Spring based on
the previous November’s submission, includes SEER incidence and population data given by age,
sex, race, year of diagnosis, and geographic area (SEER registry or county). The SEER Program
registry routinely collect data on patient demographic, primary tumor site, tumor morphology and
stage at diagnosis, first course of treatment, and follow-up for vital status. The population data
used in calculating cancer rates is obtained periodically from the Census Bureau. Also, the da-
ta available from SEER is a county-level data which provides the occurrence of a cancer within
the county as the zip-code (census tract) level data which would provide cancer incidence by the
zip-code.
4.4.2 Benzene Release Data Collection
Benzene release data were obtained from US Environmental Protection Agency (EPA) Toxic Re-
lease Inventory (TRI), which is a database containing data on disposal or other releases of over 650
toxic chemicals from thousands of U.S. facilities. EPA has been collecting TRI data since 1987,
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and the downloadable TRI Basic Data files are updated every year to include the most recent TRI
data revisions received by EPA. The data file consist of the data fields including Facility Name,
Address, Latitude &Longitude Coordinates, Chemical Identification, On-site Release Quantities
and so on (EPA 2011). However, TRI only requires the covered facilities to self report on the
benzene release. Therefore, the benzene release data in EPA’s TRI database does not cover each
parish.
The Chemical Release report that generated from EPA is given as release through:
• Fugitive Air: Fugitive air emission are all releases to air that are not released through a
confined air stream.
• Stack Air: Stack or point source air emissions occur through confined air streams such as
stack, vents, ducts, or pipes.
• Water Discharges: releases to water include discharge to streams, rivers, lakes, oceans, and
other bodies of water. This includes releases from confined sources, such as industrial pro-
cess outflow pipes or open trenches.
• Underground Injection: Underground Injection is the subsurface emplacement of fluids
through wells.
• Land: Disposal to land on site is the release of toxic chemical to land within the boundaries
of the reporting facility.
• Total On-Site Releases: On-site disposal or other releases include emissions to the air, dis-
charges to bodies of water disposal at the facility to land, and disposal in underground injec-
tion wells.
• Total Off-site Releases: An Off-site disposal or other release is a discharge of a toxic chem-
ical to the environment that occurs as a result of a facility’s transferring a waste containing a
TRI chemical off-site for disposal or other release (EPA).
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Since the main way that people exposed to benzene is through breathing, the Benzene releases
data that used in our study is the release amount through Air.
4.5 Results
4.5.1 Statistical Analysis
Crude rates of cancers provide useful summary measure to compare different sizes of populations,
but only if they have similar age compositions, because cancer’s incidence in general are sensitive
to the differences in age compositions.
For example, a county that has larger proportion of older population will have higher crude
death rates of cancer, even though its risk exposure levels may be the same as those in other
counties. So using crude rate might incorrectly attribute the high cancer rates to some characteristic
of the county other than age. An age-adjusted rate is a measure that controls for the effects of age
differences on health event rates. When comparing across geographic areas, age-adjusted rate is
used more appropriate to control for the influence that affected by age composition. The cancer
incidence rate used in this study is the number of new cancers of a specific site/type during a year
in, and it is expressed as the number of cancers per 100,000 population at risk. That is,
Incidence rate = (New Cancers / Population) × 100,000
are age-adjusted to the 2000 US Std Population (19 age groups, Census P25-1130)), and rates are
per 100,000.
4.5.2 Age-adjusted Incidence Rate for All Cancers
In Figure 4.1, we report the age-adjusted cancer incidence rate for all cancers combined for both
sexes, all age group, all races and all cancer sites. The incidence rate decreased by 1.3 percent from
2000 through 2009 (showed in Figure 4.1). There is one peak in 2001, then the rates decrease in
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2002 and 2003, but start to rise from 2004-2005. Then since 2005, the rates continuous to decrease
from 2005-2009.
*Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Figure 4.1: Incidence rate for All Cancer sites
After investigate the cancer in Louisiana from 2000-2009, then a comparison between
Louisiana and National wide was operated. Figure 4.2 shows the comparison of Age-adjusted
incidence rate for all cancers combined for both sexes, all races, and all age groups. The rates of
Louisiana are higher than U.S. rates at each year. A statistical test was performed to compare the
Louisiana rate with the U.S. rate and the obtained p-value is< 0.01, which indicates the difference
of incidence rate between Louisiana and U.S. is statistically significant.
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*Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Figure 4.2: Comparison for U.S. and Louisiana for All Cancers
4.5.3 Age-adjusted Incidence Rate for Age Group 0-19
Figure 4.3 shows the incidence rate for age group 0− 19, with both sexes, all cancers and all races
combined increased by 7.9 percent from 2000-2003, then decreasing from 2003 to 2004. The peak
of childhood cancer rates appear in 2005 with the increase rate 0.143 from 2004-2005. Then the
rates of childhood incidence drops from 15.9 per to 14.5. Since then, the rate continues to increase
again from 14.5 per 100,000 to 15.9 in 2008.
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*Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Figure 4.3: Incidence rate for All Cancer sites of Age Group 0 - 19
Figure 4.4 shows the comparison of incidence rate for age group of 0 − 19, with both sexes,
all races, all cancer sites combined. The rates of Louisiana are lower than the U.S. rates at each
year from 2000-2009. A statistical test was performed to compare the Louisiana rate with the U.S.
rate and the obtained p-value is < 0.01, which indicates the difference of incidence rate between
Louisiana and U.S. is statistically significant.
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*Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Figure 4.4: Comparison for U.S. and Louisiana for All Cancers of Age Group 0 - 19
4.5.4 Exploring Association Between Benzene Exposure and Cancer Inci-
dence
The association between age-adjusted incidence rates and the exposure of Benzene is studied.
But before investigating their relationship, we considered the time lags of 5 year,6 years, 7 years,
8 years, 9 years and 10 years, to find the year of time that been exposed to Benzene pollution
before the cancer start to develop. The graphs in Figure 4.5 to Figure 4.9 show the incidence
rate of specific cancer types versus Benzene releases at different time lags (5, 7 or 10 years). For
example, Figure 4.5 shows the graph of AML cancer rates versus Benzene release at 10 years
lag. The AML cancer rate is from 2000-2009, but the Benzene release rate is 1990-1999, then the
curve of Benzene release has been shifted 10 years later to make the curve of AML and the curve
of Benzene release be comparable.
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After study the results, Figure 4.5 shows that 10 year lag is significant for AML cancer (p −
value = 0.0295), meaning exposure to Benzene release will statistically cause AML cancer after
10 years. Figure 4.7 indicates that the time lag of 7 years is significant for bladder cancer (p −
value = 0.0092), meaning exposure to Benzene release will statistically cause Bladder after 7
years. And Figure 4.6 shows the time lag of 7 years is also significant for AML (p − value =
0.087), meaning exposure to Benzene will statistically causes AML cancer after 7 to 10 years.
Figure 4.8 shows that the time lag of 5 years is significant for NHL cancer (p − value = 0.0470)
and Prostate cancer (p− value = 0.0224), meaning exposure to Benzene release will statistically
cause NHL and Prostate cancer after 5 years. All the p-values are shown in Table 4.1.
Cancer Type Years of Lag P-value(Based on Regression Model)
AML
5 0.8399
7 0.0870*
10 0.0295*
Bladder
5 0.8657
7 0.0092*
10 0.4713
NHL
5 0.0470*
7 0.9585
10 0.9023
Prostate
5 0.0224*
7 0.3314
10 0.1855
Table 4.1: Association Between Benzene Exposure and Development of Cancers
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Figure 4.5: Benzene versus AML Cancer 10 years lag
Figure 4.6: Benzene versus AML Cancer 7 years lag
81
Figure 4.7: Benzene versus Bladder Cancer 7 years lag
Figure 4.8: Benzene versus NHL Cancer 5 years lag
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Figure 4.9: Benzene versus Prostate Cancer 5 years lag
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4.5.5 Statisticial Cluster Analysis Methodologies (SaTScan)
SaTScan is a free software that analyzes spatial, temporal and space-time data using the spatial,
temporal or space-time scan statistics. It is designed for any of the following interrelated purpose:
• Perform geographical surveillance of disease, to detect spatial or space-time disease cluster,
and to see if they are statistically significant.
• Test whether a disease is randomly distributed over space, over time or over space and time.
• Evaluate the statistical significance of disease cluster alarms.
• Perform prospective real-time or time-periodic disease surveillance for the early detection
of disease outbreaks.
The standard purely spatial scan statistic imposes a circular window on the map. The window
is in turn centered on each of several possible grid points positioned throughout the study region.
For each grid, the size of the window varies continuously from zero to the limit that specified
by the user. In total, this method creates an infinite number of distinct geographical circles with
different circles with different sets of neighboring data locations within them. Each circle is a
possible candidate cluster.
As an alternative to the circle, it is also possible to use an elliptic window shape, in which case
a set of ellipses with different shapes and angles are used as the scanning window together with
the circle. This provides slightly higher power for true clusters that are long and narrow in shape,
and slightly lower power for circular and other very compact clusters.
The space-time scan statistic is defined by a cylindrical window with a circular (or elliptic) ge-
ographic base and with height corresponding to time. The base is defined exactly as for the purely
spatial scan statistic, while the height reflects the time period of potential cluster. The cylindrical
window is then moved in space and time, so that for each possible geographical location and size,
it also visits each possible time period. In effect, we obtain an infinite number of overlapping
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cylinders of different size and shape, jointly covering the entire study region, where each cylinder
reflects a possible cluster.
The temporal scan statistic uses a window that moves in one dimension, time, defined in the
same way as the height of the cylinder used by the space-time scan statistic. This means that it
is flexible in both start and end date. The maximum temporal length is specified on the Temporal
Window Tab.
For each location and size of scanning window, the alternative hypothesis is that there is an ele-
vated risk within the window as compared to outside. Under the poisson assumption, the likelihood
function for a specific window is proportional to
( c
E[c]
)c( C − c
C − E[c]
)C−c
(4.1)
whereC is the total number of cases, c is the observed number of cases within the window andE[c]
is the covariate adjusted expected number of cases within the window under the null-hypothesis.
C − E[c] is the expected number of cases outside the window.
The likelihood function is maximized over all window locations ans sizes, and the one with the
maximum likelihood constitutes the most likely cluster. This is the cluster that is least likely to
have occurred by chance. The likelihood ratio for this window constitute the maximum likelihood
ratio test a large number of random replications of the data set generated under the null hypothesis.
The p-value is obtained through Monte Carlo hypothesis testing.
The SaTScan program scans for areas with high rates (cluster), for areas with low rates, or
simultaneously for areas with either high or low rates. The latter should be used rather than running
two separate tests for high and low rates respectively, in order to make correct statistical inference.
The most common analysis is to scan for areas with high rates, that is, for clusters.
For purely spatial and space-time analyses, SaTScan also identifies secondary cluster in the
data set in addition to the most likely cluster, and orders them according to their likelihood ratio
test statistic. There will almost always be a secondary cluster that is almost identical with the most
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likely cluster and that have almost as high likelihood value, since expanding or reducing the cluster
size only marginally will not change the likelihood very much.
4.5.6 SaTScan Results For Benzene Releases
Louisiana has the greatest concentration of crude oil refineries, natural gas processing plants and
petrochemical production facilities in the Western Hemisphere. Louisiana is the 3rd largest pro-
ducer of petroleum and the 3rd leading state in petroleum refining in the U.S. . And 25 percent of
the nation’s petrochemicals were produced in Louisiana, which consists the total value for more
than 14 billion a year.
Figure 4.10: Chemical Plants in Louisiana (online resource)
Figure 4.10 shows the Refinery and Gas plants in Louisiana. Note that there are a lot plants
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in the southwest, northwest corner, and a lot plants along the Mississippi river from Baton Rouge
to New Orleans. The cluster of Benzene release (show in Figure 4.11) shows statistical cluster
(p < 0.001)in the areas along the Mississippi river from Baton Rough to New Orleans, includ-
ing the zip-codes: 70785, 70726, 70815, 70769, 70810, 70805, 70807, 70767, 70734, 70669, 70079,
meaning these areas have statistical higher risk of the exposure of Benzene than the rest areas in
Louisiana. The cluster summary result for Benzene releases is showing below:
Satscan Summary result for Benzene Release
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 142
Total number of cases.........: 7059
Mean..........................: 118006.96
Variance......................: 19509397750.97
Standard deviation............: 139676.05
MOST LIKELY CLUSTER
1.Location IDs included.: 70785, 70726, 70815, 70769, 70810,
70805, 70807, 70767, 70734
Coordinates / radius..: (30.520028 N, 90.837611 W) / 38.40 km
Number of cases.......: 1479
Mean inside...........: 292611.67
Mean outside..........: 71727.33
Variance..............: 11427610828.97
Standard deviation....: 106900.00
Log likelihood ratio..: 1887.801979
P-value...............: 0.001
SECONDARY CLUSTERS
2.Location IDs included.: 70669
87
Coordinates / radius..: (30.252222 N, 93.284444 W) / 0 km
Number of cases.......: 519
Mean inside...........: 260665.92
Mean outside..........: 106685.86
Variance..............: 17894112489.35
Standard deviation....: 133768.88
Log likelihood ratio..: 305.035406
P-value...............: 0.001
3.Location IDs included.: 70079
Coordinates / radius..: (29.985278 N, 90.392778 W) / 0 km
Number of cases.......: 294
Mean inside...........: 205567.57
Mean outside..........: 114201.67
Variance..............: 19176156623.96
Standard deviation....: 138478.00
Log likelihood ratio..: 60.808416
P-value...............: 0.001
Since the zip-code data were used in our study, the summary result shows the zip-codes that
be included into the clusters. For each zip-code area and size of scanning window, the alterna-
tive hypothesis is that there is an elevated risk within the window as compared to outside. And
under the poisson assumption, the likelihood function for each window is calculated using 4.1.
And the likelihood function is maximized over all window locations and sizes, the one with the
maximum likelihood constitute the most likely cluster. So, zip-code areas: 70785, 70726, 70815,
70769, 70810, 70805, 70807, 70767, 70734 has the mostly likely clusters, and they have statistical
significant higher risk than the other areas in Louisiana (p− value = 0.001).
Remark 2 Cluster areas of Benzene releases are the locations that have a large amount of refinery
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and gas plants.
Figure 4.11: Clusters of Benzene released in Louisiana
4.5.7 SaTScan Results For Cancers
Figure 4.12 - 4.18 shows the clusters of AML, NHL, Bladder (1st round), Bladder (2nd round),
Breast, Childhood Brain and Prostate cancers, respectively. The shaded the area are the parishes
that have statistical significant risk of cancers compare to the rest areas in Louisiana.
Remark 3 The cluster areas of AML and NHL are in regions near petrochemical, refinery, and
gas plants, which would most likely release Benzene into the environment.
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Figure 4.12: Clusters of AML Cancer in Louisiana
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Figure 4.13: Clusters of NHL cancer in Louisiana
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The following is the cluster results of Bladder cancer that generated from SaTScan, and map
of the cluster is showing in Figure 4.14. The SUMMARY OF DATA shows the data period is from
2000 to 2009, the number of locations is 64 which is the number of parishes in Louisiana. Total
population is the average population from study period 2000 to 2009. The most likely cluster and
second likely cluster include 19 parishes and they are both significant with p-value = 0.0000075
and 0.0058 for most and second likely cluster, respectively. The relative risk is the estimated risk
within the cluster divided by the estimated risk outside the cluster. The most likely cluster relative
risk is 1.15, meaning the risk of Bladder cancer inside the cluster is 15 percent higher than areas
outside of the cluster.
Satscan Summary result for Bladder Cancer 1st round
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 4217086
Total number of cases.........: 7975
Annual cases / 100000.........: 18.9
MOST LIKELY CLUSTER
1.Location IDs included.: 506, 490, 508, 516, 505, 487, 464,
493, 499, 513
Coordinates / radius..: (29.550000 N, 90.200000 W) / 100.72 km
Population............: 1142575
Number of cases.......: 2381
Expected cases........: 2160.74
Annual cases / 100000.: 20.8
Observed / expected...: 1.10
Relative risk.........: 1.15
Log likelihood ratio..: 15.088557
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P-value...............: 0.0000075
SECONDARY CLUSTERS
2.Location IDs included.: 504, 510, 482, 502, 469, 521, 470,
472, 523
Coordinates / radius..: (31.290000 N, 93.300000 E) / 12903.07 km
Population............: 534082
Number of cases.......: 1133
Expected cases........: 1010.01
Annual cases / 100000.: 21.2
Observed / expected...: 1.12
Relative risk.........: 1.14
Log likelihood ratio..: 8.293813
P-value...............: 0.0058
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With the parishes that been selected from 1st round cluster analysis, we use the same procedure
for the selected 19 parishes to do the 2nd round cluster analysis. Figure 4.15 shows the clusters of
Bladder cancer from the 2nd round analysis. The detail of the result is given in Appendix.
Remark 4 The cluster areas of Bladder Cancer are in regions near petrochemical, refinery, and
gas plants, which would most likely release Benzene into the environment.
Figure 4.14: Clusters of Bladder Cancer first round in Louisiana
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Figure 4.15: Clusters of Bladder Cancer second round in Louisiana
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Figure 4.16: Clusters of Breast Cancer in Louisiana
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Figure 4.17: Clusters of Childhood Brain cancer in Louisiana
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Figure 4.18: Clusters of Prostate cancer 2nd round in Louisiana
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4.5.8 Discussion
In the Chapter 4, we have demonstrated a correlation between the exposure to Benzene and the
incidence of several cancers. However, it should be noted that a mere correlation does not establish
a causal relationship between exposure to Benzene and the incidence of a cancer. The author
recommends that the causal relationship needs to be further investigated by researchers.
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Appendix A
SEER Database
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Number of Person by Race and Hispanic Ethnicity for SEER Participants (2010 Census Data1)
Total U.S. 308,745,538 223,553,265 38,929,319 2,932,248 14,674,252 540,013 19,107,368 9,009,073 3,347,229 2,555,923 763,325 50,477,594
Total SEER 86,355,485 55,638,167 9,975,844 1,284,768 7,390,717 358,915 8,352,748 3,354,326 1,671,615 1,657,543 535,004 19,366,596
SEER - % of U.S. 28.0% 24.9% 25.6% 43.8% 50.4% 66.5% 43.7% 37.2% 49.9% 64.9% 70.1% 38.4%
SEER - 9 % of U.S. 9.4% 8.7% 8.8% 12.5% 17.7% 43.3% 8.3% 14.1% 20.3% 22.2% 36.6% 7.9%
SEER - 11 % of U.S. 13.4% 11.5% 11.1% 15.7% 31.0% 49.9% 21.5% 20.3% 36.8% 38.8% 53.9% 18.8%
SEER - 13 % of U.S. 13.4% 11.5% 11.3% 19.3% 31.0% 49.9% 21.6% 20.4% 36.8% 38.8% 53.9% 18.8%
SEER - 17 % of U.S. 25.8% 23.0% 21.6% 30.0% 49.7% 65.5% 42.7% 35.9% 49.6% 64.4% 69.7% 37.5%
SEER - 18 % of U.S. 27.8% 24.9% 25.6% 30.6% 50.4% 66.5% 43.7% 37.2% 49.9% 64.9% 70.1% 38.4%
NORTHEAST
  Connecticut 3,574,097 2,772,410 362,296 11,256 135,565 1,428 198,466 92,676 31,404 11,998 3,574 479,087
  New Jersey 8,791,894 6,029,248 1,204,826 29,026 725,726 3,043 559,722 240,303 134,442 110,650 13,146 1,555,144
SOUTH
  Kentucky 4,339,367 3,809,537 337,520 10,120 48,930 2,501 55,551 75,208 9,051 5,188 4,124 132,836
  Louisiana 4,533,372 2,836,192 1,452,396 30,579 70,132 1,963 69,227 72,883 10,017 6,416 1,464 192,560
  Atlanta 3,365,297 1,546,399 1,314,721 12,055 215,881 1,639 187,289 87,313 32,980 6,996 4,322 422,202
  Rural Georgia 127,159 71,315 51,120 294 550 36 2,436 1,408 66 72 10 4,429
  Greater Georgia6 6,195,197 4,169,726 1,584,594 19,802 98,036 5,124 199,147 118,768 12,803 10,855 3,326 427,058
NORTH CENTRAL
  Detroit 3,863,924 2,598,821 974,744 13,013 138,806 837 49,885 87,818 20,911 14,866 6,604 156,275
  Iowa 3,046,355 2,781,561 89,148 11,084 53,094 2,003 56,132 53,333 9,834 3,558 1,332 151,544
WEST
  Hawaii 1,360,301 336,599 21,424 4,164 525,078 135,422 16,985 320,629 54,955 197,497 185,502 120,842
  New Mexico 2,059,179 1,407,876 42,550 193,222 28,208 1,810 308,503 77,010 5,729 4,963 2,208 953,403
  Seattle-Puget Sound 4,590,294 3,444,989 212,146 63,217 434,419 34,169 165,279 236,075 85,135 83,304 30,777 399,157
  Utah 2,763,885 2,379,560 29,287 32,927 55,285 24,554 166,754 75,518 11,186 5,600 6,087 358,340
  San Francisco-Oakalnd 4,335,391 2,239,519 363,905 24,774 1,005,823 31,832 429,754 239,784 428,403 239,232 39,310 938,794
  San Jose-Monterey 2,514,350 1,292,722 62,462 21,572 608,337 9,574 396,058 123,625 158,494 102,589 29,576 824,491
  Los Angeles 9,818,605 4,936,599 856,874 72,828 1,346,865 26,094 2,140,632 438,713 393,488 322,110 102,287 4,687,889
  Greater California7 20,585,610 12,985,094 1,015,831 243,627 1,899,982 76,886 3,350,928 1,013,262 272,717 531,649 101,355 7,562,545
  Arizona8 296,529 296,529
  Alaska8 104,871 104,871
  Cherokee Nation8 89,808 89,808
1. Source: U.S. Bureau of Census, Census 2010, Summary File 1, Table DP-1.
2. Total Population equals the sum of the White, Black, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, Other Race, and Two or 
    More Races columns. Note that only the American Indian/Alaska Native populations are covered in the SEER areas of Arizona, Alaska, and Cherokee Nation.
3. Since each person could report multiple races in the 2010 Census, race-specific counts and percentages in this table are based on persons self-reporting only one race.
4. The Chinese, Filipino, and Japanese populations are also included within the "Asian" population.
5. Hispanic ethnicity is tabulated independently of race, so Hispanic persons may be of any race.
6. Greater Georgia calculated by subtracting the number for Atlanta and Rural Georgia from the Georgia state totals.
7. Greater California calculated by subtracting the number for San Francisco-Oakland, San Jose-Monterey and Los Angeles from the California state totals.
8. Only the American Indian/Alaska Native populations within these states/areas are covered by SEER.
Native 
Hawaiian/ 
Pacific 
Islander3
American 
Indian/ 
Alaska 
Native3
Total 
Population2
White3 Black3 Asian3 Hispanic5
Other       
Race3
2 or More 
Races Chinese
3,4 Filipino3,4 Japanese 3, 4
http://seer.cancer.gov/registries/data.html
Figure A.1: SEER database
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Figure A.2: Benzene versus Bladder Cancer 10 years lag
Figure A.3: Benzene versus Childhood brain Cancer 10 years lag
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Figure A.4: Benzene versus childhood Leukemia Cancer 10 years lag
Figure A.5: Benzene versus Childhood Lymphoma Cancer 10 years lag
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Figure A.6: Benzene versus Breast Cancer 5 years lag
Figure A.7: Benzene versus NHL Cancer 10 years lag
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Figure A.8: Benzene versus Prostate Cancer 10 years lag
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Figure A.9: Benzene versus Childhood Brain Cancer 7 years lag
110
Figure A.10: Benzene versus Childhood Leukemia Cancer 7 years lag
Figure A.11: Benzene versus Childhood Lymphoma Cancer 7 years lag
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Figure A.12: Benzene versus Breast Cancer 5 years lag
Figure A.13: Benzene versus NHL Cancer 7 years lag
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Figure A.14: Benzene versus Prostate Cancer 7 years lag
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Figure A.15: Benzene versus AML Cancer 5 years lag
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Figure A.16: Benzene versus Bladder Cancer 5 years lag
Figure A.17: Benzene versus Childhood Brain Cancer 5 years lag
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Figure A.18: Benzene versus Childhood Leukemia Cancer 5 years lag
Figure A.19: Benzene versus Childhood Lymphoma Cancer 5 years lag
116
Figure A.20: Benzene versus Breast Cancer 5 years lag
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Appendix B
Cluster Results
B.0.9 Coordinates for Each Parish
State_county County Latitude Longitude
462 ACADIA 30.13 -92.22
463 ALLEN 31.5 -93.17
464 ASCENSION 30.12 -90.56
465 ASSUMPTION 29.55 -91.5
466 AVOYELLES 30.58 -92.3
467 BEAUREGARD 30.45 -93.2
468 BIENVILLE 32.21 -92.58
469 BOSSIER 32.45 -93.39
470 CADDO 32.36 -93.51
471 CALCASIEU 30.12 -93.2
472 CALDWELL 32.4 -92.3
473 CAMERON 29.47 -93.19
474 CATAHOULA 30.12 -91.42
475 CLAIBORNE 32.3 -92.11
476 CONCORDIA 31.28 -91.38
477 DE SOTO 32.1 -93.39
478 EAST BATON ROUGE 30.34 -91.5
479 EAST CARROLL 32.45 -91.15
480 EAST FELICIANA 30.5 -91.1
481 EVANGELINE 30.46 -92.22
482 FRANKLIN 33.46 -118.1
483 GRANT 30.47 -92.56
484 IBERIA 29.55 -91.36
485 IBERVILLE 30.17 -91.24
486 JACKSON 30.5 -91.13
487 JEFFERSON 29.57 -90.9
488 JEFFERSON DAVIS 30.16 -92.49
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489 LAFAYETTE 30.13 -92.1
490 LAFOURCHE 29.41 -90.31
491 LASALLE 29.57 -92.1
492 LINCOLN 32.35 -92.41
493 LIVINGSTON 30.3 -90.44
494 MADISON 32.26 -91.17
495 MOREHOUSE 32.27 -91.45
496 NATCHITOCHES 31.45 -93.5
497 ORLEANS 30.6 -89.53
498 OUACHITA 32.25 -92.13
499 PLAQUEMINES 29.19 -89.28
500 POINTE COUPEE 30.36 -91.35
501 RAPIDES 31.8 -92.32
502 REDRIVER 32.5 -93.22
503 RICHLAND 32.23 -91.47
504 SABINE 31.29 93.3
505 ST BERNARD 29.52 -89.51
506 ST CHARLES 29.55 -90.2
507 ST HELENA 30.48 -90.4
508 ST JAMES 29.58 -90.49
509 ST JOHN THE BAPTIST 30.6 -90.29
510 ST LANDRY 30.36 92.3
511 ST MARTIN 30.14 -91.45
512 ST MARY 29.3 -91.26
513 ST TAMMANY 30.26 -89.55
514 TANGIPAHOA 30.52 -90.3
515 TENSAS 32.4 -91.17
516 TERREBONNE 29.13 -90.45
517 UNION 17.58 -76.47
518 VERNILION 29.51 -92.22
519 VERNON 32.23 -92.34
520 WASHINGTON 30.36 -92.3
521 WEBSTER 32.45 -93.2
522 WEST BATON ROUGE 30.28 -91.19
523 WEST CARROLL 32.45 -91.28
524 WEST FELICIANA 30.5 -91.24
525 WINN 31.55 -92.39
B.0.10 Cluster Results for Benzene Releases
119
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2010/12/31
Number of locations...........: 142
Total number of cases.........: 7059
Mean..........................: 118006.96
Variance......................: 19509397750.97
Standard deviation............: 139676.05
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 70785, 70726, 70815, 70769, 70810,
70805, 70807, 70767, 70734
Coordinates / radius..: (30.520028 N, 90.837611 W) / 38.40 km
Number of cases.......: 1479
Mean inside...........: 292611.67
Mean outside..........: 71727.33
Variance..............: 11427610828.97
Standard deviation....: 106900.00
Log likelihood ratio..: 1887.801979
P-value...............: 0.001
SECONDARY CLUSTERS
2.Location IDs included.: 70669
Coordinates / radius..: (30.252222 N, 93.284444 W) / 0 km
Number of cases.......: 519
Mean inside...........: 260665.92
Mean outside..........: 106685.86
Variance..............: 17894112489.35
Standard deviation....: 133768.88
Log likelihood ratio..: 305.035406
P-value...............: 0.001
3.Location IDs included.: 70079
Coordinates / radius..: (29.985278 N, 90.392778 W) / 0 km
Number of cases.......: 294
Mean inside...........: 205567.57
Mean outside..........: 114201.67
Variance..............: 19176156623.96
Standard deviation....: 138478.00
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Log likelihood ratio..: 60.808416
P-value...............: 0.001
B.0.11 Cluster Results for AML Cancer
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 1225348
Total number of cases.........: 8127
Annual cases / 100000.........: 66.3
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 487
Coordinates / radius..: (29.570000 N, 90.900000 W) / 0 km
Population............: 112256
Number of cases.......: 925
Expected cases........: 744.53
Annual cases / 100000.: 82.4
Observed / expected...: 1.24
Relative risk.........: 1.27
Log likelihood ratio..: 22.517434
P-value...............: 0.0000000039
SECONDARY CLUSTERS
2.Location IDs included.: 471, 467, 488, 473, 483, 520, 462
Coordinates / radius..: (30.120000 N, 93.200000 W) / 94.20 km
Population............: 107004
Number of cases.......: 858
Expected cases........: 709.69
Annual cases / 100000.: 80.2
Observed / expected...: 1.21
Relative risk.........: 1.23
Log likelihood ratio..: 16.009715
P-value...............: 0.0000025
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B.0.12 Cluster Results for Bladder Cancer 1st round
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 4217086
Total number of cases.........: 7975
Annual cases / 100000.........: 18.9
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 506, 490, 508, 516, 505, 487, 464,
493, 499, 513
Coordinates / radius..: (29.550000 N, 90.200000 W) / 100.72 km
Population............: 1142575
Number of cases.......: 2381
Expected cases........: 2160.74
Annual cases / 100000.: 20.8
Observed / expected...: 1.10
Relative risk.........: 1.15
Log likelihood ratio..: 15.088557
P-value...............: 0.0000075
SECONDARY CLUSTERS
2.Location IDs included.: 504, 510, 482, 502, 469, 521, 470,
472, 523
Coordinates / radius..: (31.290000 N, 93.300000 E) / 12903.07 km
Population............: 534082
Number of cases.......: 1133
Expected cases........: 1010.01
Annual cases / 100000.: 21.2
Observed / expected...: 1.12
Relative risk.........: 1.14
Log likelihood ratio..: 8.293813
P-value...............: 0.0058
122
B.0.13 Cluster Results for Bladder Cancer 2nd round
MOST LIKELY CLUSTER
1.Location IDs included.: 499, 505
Coordinates / radius..: (29.190000 N, 89.280000 W) / 42.91 km
Population............: 72561
Number of cases.......: 183
Expected cases........: 152.08
Annual cases / 100000.: 25.2
Observed / expected...: 1.20
Relative risk.........: 1.21
Log likelihood ratio..: 3.093031
P-value...............: 0.0201
SECONDARY CLUSTERS
2.Location IDs included.: 487, 508
Coordinates / radius..: (29.570000 N, 90.900000 W) / 39.64 km
Population............: 443742
Number of cases.......: 986
Expected cases........: 930.01
Annual cases / 100000.: 22.2
Observed / expected...: 1.06
Relative risk.........: 1.08
Log likelihood ratio..: 2.263612
P-value...............: 0.0386
3.Location IDs included.: 504, 510, 482
Coordinates / radius..: (31.290000 N, 93.300000 E) / 12089.71 km
Population............: 126718
Number of cases.......: 297
Expected cases........: 265.58
Annual cases / 100000.: 23.4
Observed / expected...: 1.12
Relative risk.........: 1.13
Log likelihood ratio..: 1.941892
P-value...............: 0.514
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B.0.14 Cluster Results for Breast Cancer
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 2170697
Total number of cases.........: 27779
Annual cases / 100000.........: 128.0
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 513
Coordinates / radius..: (30.260000 N, 89.550000 W) / 0 km
Population............: 103190
Number of cases.......: 1507
Expected cases........: 1320.55
Annual cases / 100000.: 146.0
Observed / expected...: 1.14
Relative risk.........: 1.15
Log likelihood ratio..: 13.241345
P-value...............: 0.000043
SECONDARY CLUSTERS
2.Location IDs included.: 487
Coordinates / radius..: (29.570000 N, 90.900000 W) / 0 km
Population............: 220118
Number of cases.......: 3073
Expected cases........: 2816.90
Annual cases / 100000.: 139.6
Observed / expected...: 1.09
Relative risk.........: 1.10
Log likelihood ratio..: 12.621949
P-value...............: 0.000079
B.0.15 Cluster Results for Childhood Brain Cancer
SUMMARY OF DATA
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Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 2170697
Total number of cases.........: 312
Annual cases / 100000.........: 1.4
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 499, 505, 506, 490, 516
Coordinates / radius..: (29.190000 N, 89.280000 W) / 113.73 km
Population............: 157533
Number of cases.......: 38
Expected cases........: 22.64
Annual cases / 100000.: 2.4
Observed / expected...: 1.68
Relative risk.........: 1.77
Log likelihood ratio..: 4.732177
P-value...............: 0.0127
SECONDARY CLUSTERS
2.Location IDs included.: 525, 501, 463, 468, 519, 498
Coordinates / radius..: (31.550000 N, 92.390000 W) / 81.56 km
Population............: 186315
Number of cases.......: 39
Expected cases........: 26.78
Annual cases / 100000.: 2.1
Observed / expected...: 1.46
Relative risk.........: 1.52
Log likelihood ratio..: 2.706160
P-value...............: 0.0696
B.0.16 Cluster Results for Childhood Lymphoma Cancer
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Figure B.1: Clusters of childhood Lymphoma cancer in Louisiana
126
MOST LIKELY CLUSTER
1.Location IDs included.: 523
Coordinates / radius..: (32.450000 N, 91.280000 W) / 0 km
Population............: 3051
Number of cases.......: 5
Expected cases........: 1.06
Annual cases / 100000.: 16.4
Observed / expected...: 4.72
Relative risk.........: 4.77
Log likelihood ratio..: 3.840272
P-value...............: 0.376
SECONDARY CLUSTERS
2.Location IDs included.: 513
Coordinates / radius..: (30.260000 N, 89.550000 W) / 0 km
Population............: 59710
Number of cases.......: 34
Expected cases........: 20.71
Annual cases / 100000.: 5.7
Observed / expected...: 1.64
Relative risk.........: 1.70
Log likelihood ratio..: 3.786368
P-value...............: 0.406
B.0.17 Cluster Results for NHL Cancer
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 4217086
Total number of cases.........: 8127
Annual cases / 100000.........: 19.3
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 471, 467, 488, 473, 483, 520, 462
Coordinates / radius..: (30.120000 N, 93.200000 W) / 94.20 km
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Population............: 361682
Number of cases.......: 858
Expected cases........: 697.02
Annual cases / 100000.: 23.7
Observed / expected...: 1.23
Relative risk.........: 1.26
Log likelihood ratio..: 19.060507
P-value...............: 0.00000018
SECONDARY CLUSTERS
2.Location IDs included.: 465, 484, 512, 487
Coordinates / radius..: (29.550000 N, 91.500000 W) / 58.04 km
Population............: 565113
Number of cases.......: 1212
Expected cases........: 1089.06
Annual cases / 100000.: 21.4
Observed / expected...: 1.11
Relative risk.........: 1.13
Log likelihood ratio..: 7.771498
P-value...............: 0.011
B.0.18 Cluster Results for Prostate Cancer First Round
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 64
Total population..............: 2063593
Total number of cases.........: 32673
Annual cases / 100000.........: 158.3
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 467, 471, 483, 488, 520, 466, 481,
462, 473, 489, 496, 463, 518, 491,
525, 478, 511, 501, 474, 500, 477,
524, 485, 465, 522, 476, 486, 480,
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484, 468, 519, 470, 521, 469
Coordinates / radius..: (30.450000 N, 93.200000 W) / 222.98 km
Population............: 1004398
Number of cases.......: 17111
Expected cases........: 15902.70
Annual cases / 100000.: 170.3
Observed / expected...: 1.08
Relative risk.........: 1.16
Log likelihood ratio..: 89.397814
P-value...............: < 0.000000000000000010
B.0.19 Cluster Results for Prostate Cancer Second Round
SUMMARY OF DATA
Study period..................: 2000/1/1 to 2009/12/31
Number of locations...........: 34
Total population..............: 1004398
Total number of cases.........: 17111
Annual cases / 100000.........: 170.3
________________________________________________________________
MOST LIKELY CLUSTER
1.Location IDs included.: 469, 470, 521, 477, 468
Coordinates / radius..: (32.450000 N, 93.390000 W) / 80.60 km
Population............: 200122
Number of cases.......: 3862
Expected cases........: 3409.29
Annual cases / 100000.: 193.0
Observed / expected...: 1.13
Relative risk.........: 1.17
Log likelihood ratio..: 36.371120
P-value...............: 0.0000000000000016
SECONDARY CLUSTERS
2.Location IDs included.: 478, 500
Coordinates / radius..: (30.340000 N, 91.500000 W) / 14.56 km
Population............: 202286
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Number of cases.......: 3739
Expected cases........: 3446.16
Annual cases / 100000.: 184.8
Observed / expected...: 1.08
Relative risk.........: 1.11
Log likelihood ratio..: 15.264774
P-value...............: 0.0000025
3.Location IDs included.: 473, 471, 518, 488, 491
Coordinates / radius..: (29.470000 N, 93.190000 W) / 105.99 km
Population............: 137341
Number of cases.......: 2529
Expected cases........: 2339.76
Annual cases / 100000.: 184.1
Observed / expected...: 1.08
Relative risk.........: 1.09
Log likelihood ratio..: 8.672220
P-value...............: 0.0019
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Appendix C
R Source Code for Single-stage Procedure
cc <- 800
kk<-4
q1<-2
q2<-2
std<-1
bb<- 3.5938
a <- bb*std / cc
delta2 <- a
delta1 <- -delta2
csize<-1
itersize<-5000
pvalue<-rep(1.,itersize)
cat("q1=",q1,"q2=",q2,"\n")
cat("bb=",bb,"\n")
cat("standard deviation for each group=",std,"\n")
cat("delta1=",delta1,"delta2=",delta2,"\n")
cat("No. of Iterations=",itersize,"\n")
cat("kk=",kk,"control size=",csize,"\n")
for(iter in 1:itersize){
min1<-rep(0.,kk)
pzeromin<-rep(0.,csize)
m1<-rep(0.,kk)
pzeromean<-rep(0.,csize)
mdat <- matrix(rexp(kk*cc,1), nrow = cc, ncol=kk, byrow=TRUE)
pzero <- matrix(rexp(csize*cc,1), nrow = cc, ncol=csize, byrow=TRUE)
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#create LFC
for(j1 in 1:q1){
mdat[,j1]<-std*mdat[,j1]+delta1}
for(j2 in (q1+1):(q1+q2)){
mdat[,j2]<-std*mdat[,j2]+delta2}
for(j in 1:csize){
pzero[,j]<-std*pzero[,j]}
ones <- rep(1., cc)
onescsize <- rep(1., csize)
#computation of minium and mean
for(j in 1:kk){
min1[j] <- min(mdat[,j])
m1[j]<-(1/10)*t(ones)%*% mdat[,j]}
for(j in 1:csize){
pzeromin[j] <- min(pzero[,j])
pzeromean[j]<-(1/cc)*t(ones)%*% pzero[,j]}
pzerominallc <- t(onescsize) %*% min(pzeromin)
pzeromeanallc<-(1/csize)*t(onescsize) %*% pzeromean
#compute if CD is met or not
for(j1 in 1:q1){
if((min1[j1]-pzerominallc) > (delta1+delta2)/2) pvalue[iter]<-0}
for(j2 in (q1+1):(q1+q2)){
if((min1[j2]-pzerominallc)< (delta1+delta2)/2) pvalue[iter]<-0}
}
pbar <- mean(pvalue)
pvar <- var(pvalue)
pstdev <-pvar^(0.5) /(itersize) ^0.5
cat(" cc ", " pbar ", " s(pbar) ","delta", "a" , "sigma","\n")
cat(cc, " ", round(pbar, digits=4)," ", round(pstdev, digits=4),"", delta1, " " , a, " ", std, "\n")
itersize
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Appendix D
R Source Code for Purely Sequential Procedure
cc <- 800
kk<-4
q1<-2
q2<-2
std<-2
bb<- 3.5938
a <- bb*std / cc
delta2 <- a
delta1 <- -delta2
csize<-1
itersize<-2000
nvalue<-rep(0.,itersize)
pvalue<-rep(1.,itersize)
cat("q1=",q1,"q2=",q2,"\n")
cat("bb=",bb,"\n")
cat("standard deviation for each group=",std,"\n")
cat("delta1=",delta1,"delta2=",delta2,"\n")
cat("No. of Iterations=",itersize,"\n")
cat("kk=",kk,"control size=",csize,"\n")
for(iter in 1:itersize){
min1<-rep(0.,kk)
pzeromin<-rep(0.,csize)
m1<-rep(0.,kk)
pzeromean<-rep(0.,csize)
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v1<-rep(0.,kk)
result1 <- rep(0.,kk)
vcontrol<-rep(0.,csize)
result2 <- rep(0.,csize)
totalsize<-2*cc
mdat <- matrix(rexp(kk*totalsize,1), nrow = totalsize, ncol=kk, byrow=TRUE)
pzerofull <- matrix(rexp(csize*totalsize,1), nrow = totalsize, ncol=csize, byrow=TRUE)
#create LFC
for(j1 in 1:q1){
mdat[,j1]<-std*mdat[,j1]+delta1}
for(j2 in (q1+1):(q1+q2)){
mdat[,j2]<-std*mdat[,j2]+delta2}
for(j in 1:csize){
pzerofull[,j]<-std*pzerofull[,j]}
#sequential procedure starts
for(n1 in 10:totalsize){
#.....MATRIX APPROACH....create a matrix "xdat" with data which is already generated for the iteration.
#......andn pzero with czise columns
xdat <- matrix(0, nrow = n1, ncol=kk, byrow=TRUE)
pzero <- matrix(0, nrow = n1, ncol=csize, byrow=TRUE)
#...first xdat matrix
for(i in 1:n1){
for(j in 1:kk){
xdat[i,j]<-mdat[i,j]}}
#....next the pzero matrix
for(i in 1:n1){
for(j in 1:csize){
pzero[i,j]<-pzerofull[i,j]}}
ones <- rep(1., n1)
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oneskk <- rep(1., kk)
onescsize <- rep(1.,csize)
#computation of minium and mean
for(j in 1:kk){
min1[j] <- min(xdat[,j])
m1[j]<-(1/n1)*t(ones)%*% xdat[,j]}
for(j in 1:csize){
pzeromin[j] <- min(pzero[,j])
pzeromean[j]<-(1/n1)*t(ones)%*% pzero[,j]}
pzerominallc <- t(onescsize) %*% min(pzeromin)
pzeromeanallc<-(1/csize)*t(onescsize)%*% pzeromean
#computation of variance
#for population groups
for(j in 1:kk){
result1[j] <- t(ones)%*%(xdat[,j]-min1[j])
}
#variance for control groups
for(j in 1:csize){
result2[j] <- t(ones)%*%(pzero[,j]-pzeromin[j])
}
#pooled variance
#vp <- (t(ones)%*%(xdat[,j] - t(min1[j]%*%t(ones) ))+ t(ones)%*%(pzero[,j] - t(pzeromin[j]%*%t(ones))) )/((kk+1)*(n1-1))
#vp <- (t(ones)%*%(xdat[,j]-min1[j]) + t(ones)%*%(pzero[,j]-pzeromin[j]) )/((kk+1)*(n1-1))
vp<- (t(oneskk)%*%result1+t(onescsize)%*% result2)/((kk+1)*(n1-1))
#vp<- (vppopu+vpcontrol)/(kk+csize)
#cat("pooled var",vp,"\n")
term <- bb*vp/a
#cat("n1=",n1,"term=",term,"\n")
if(n1 > term) break
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}nvalue[iter]<-n1
#cat("nvalue=",nvalue,"\n")
#compute if CD is met or not
for(j1 in 1:q1){
if((min1[j1]-pzerominallc)>(delta1+delta2)/2) pvalue[iter]<-0}
for(j2 in (q1+1):(q1+q2)){
if((min1[j2]-pzerominallc)<(delta1+delta2)/2) pvalue[iter]<-0}
}
nbar<-mean(nvalue)
nvar<-var(nvalue)
nstdev <- nvar^(0.5)/(itersize)^0.5
pbar <- mean(pvalue)
pvar <- var(pvalue)
pstdev <- pvar^(0.5)/(itersize)^0.5
cat(" cc ", " nbar ", " s(nbar) ", " pbar ", " s(pbar) ","\n")
cat(round(cc,digits = 4), " ", nbar," ", round(nstdev, digits=4), " ", round(pbar, digits=4)," ", round(pstdev, digits=4),"\n")
itersize
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